{
  "title": "M21-1, Part V, Subpart iii, Chapter 5 - Cardiovascular System Conditions",
  "url": "https://www.knowva.ebenefits.va.gov/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000014520/M21-1-Part-V-Subpart-iii-Chapter-5-Cardiovascular-System-Conditions",
  "content": "﻿﻿\n<-- Previous Section\nNext Section -->\nOverview\nIn This Chapter\nThis chapter contains the following topics:\nTopic\nTopic Name\n1\nRating Principles for Heart Conditions\n2\nEvaluating Diseases of the Heart\n3\nRating Principles for Hypertension\n4\nResiduals of Cold Injuries\n5\nOther Cardiovascular Disabilities\n1\n.\nRating Principles for Heart Conditions\nIntroduction\nThis topic contains miscellaneous cardiovascular concepts and principles, including\ndefinition of arteriosclerotic heart disease\ndocumentation required to support a diagnosis of arteriosclerotic heart disease\nmanifestations of advanced arteriosclerotic disease in service\ndocumentation of myocardial infarction (MI)\neffective dates and liberalizing changes affecting service connection (SC) for ischemic heart disease (IHD)\nconsidering cardiovascular conditions subsequent to amputation\neffects of rheumatic heart disease\n, and\ndefinition of congenital heart defects.\nChange Date\nFebruary 5, 2024\nV.iii.5.1.a\n.\nDefinition:  Arteriosclerotic Heart Disease\nArteriosclerotic heart disease\n, also diagnosed as ischemic heart disease (IHD) and coronary artery disease (CAD), is a disease of the heart caused by the diminution of blood supply to the heart muscle due to narrowing of the cavity of one or both coronary arteries due to the accumulation of fatty material on the inner lining of the arterial wall.\nNote\n:  IHD refers only to heart disease, and therefore, does not include hypertension or peripheral manifestations of arteriosclerosis such as peripheral vascular disease or stroke.  Consider presumptive service connection (SC) for IHD under\n38 CFR 3.309(e)\n.\nReference\n:  For more information on the definition of IHD, see\n38 CFR 3.309(e)\n, and\nM21-1, Part VIII, Subpart i, 2.B.1.c\n.\nV.iii.5.1.b\n.\nDocumentation Required to Support a Diagnosis of Arteriosclerotic Heart Disease\nFor rating purposes, a diagnosis of arteriosclerotic heart disease must be documented by objective testing.  Objective tests include, but are not limited to\nelectrocardiogram (ECG or EKG) findings\ntreadmill exercise testing (with or without a thallium scan),or\ncardiac catheterization and angiography.\nNote\n:  The actual test results\ndo not\nneed to be of record if the evidence indicates that the diagnosis was rendered by a competent medical professional\nand\nbased on the results of an objective test.\nImportant\n:  Symptoms of chest pain alone are\nnot\nsufficient to support a clinical diagnosis of arteriosclerotic heart disease for rating purposes.  As chest pain is a symptom of multiple disabilities, the diagnosis of arteriosclerotic heart disease\nmust\nbe supported with objective documentation.\nV.iii.5.1.c\n.\nManifestations of Advanced Arteriosclerotic Disease in Service\nWhen SC for a cardiovascular condition is claimed, the mere identification of arteriosclerotic disease upon routine examination early in service is\nnot\na basis for SC.\nManifestation of lesions or symptoms of chronic disease will establish pre-service existence under\n38 CFR 3.303(c)\nif objective evidence shows manifestation\nfrom date of enlistment, or\nso close to enlistment that chronic disease could not have originated during service.\nImportant\n:\nAn analysis of the presumption of soundness under\n38 CFR 3.304\nand the provisions on aggravation under\n38 CFR 3.306\nmay be required.\nGrant SC for any sudden development during service of coronary occlusion or thrombosis whether or not these are manifestations of advanced long-standing arteriosclerotic disease.\nNote\n:  Under\n38 CFR 3.6(a)\n, inactive duty for training qualifies as active service if an individual becomes disabled or dies from an acute myocardial infarction (MI), a cardiac arrest, or a cerebrovascular accident occurring during such training.\nV.iii.5.1.d\n.\nDocumentation of MI\n38 CFR 4.104, diagnostic code (DC) 7006\nrequires documentation of an MI by laboratory tests.  Health providers may rely on a variety of diagnostic tests to document MI.\nTesting may include, but is not limited to,\nEKG\ncardiac enzymes (Troponin, CKMB), and\nradionuclide imaging.\nThe\nHeart Conditions Disability Benefits Questionnaire\n(DBQ) elicits information about testing conducted in support of cardiac workup.\nIf an assessment of an MI appears to have been made without diagnostic testing or if there is a question about whether the assessment was supported by appropriate testing, obtain clarification from the Department of Veterans Affairs (VA) examiner or other provider.\nReference\n:  For more information on evaluating medical evidence, see\nM21-1, Part V, Subpart ii, 1.A.3\n.\nV.iii.5.1.e\n.\nEffective Dates and Liberalizing Changes Affecting SC for IHD\nIHD became a condition presumptively associated with herbicide exposure effective August 31, 2010.  This was a liberalizing change of law.\nTherefore, unless an earlier effective date is available under the provisions of\n38 CFR 3.816\n, consider the application of\n38 CFR 3.114(a)\nwhen granting presumptive SC for IHD related to herbicide exposure under the provisions of\n38 CFR 3.307(a)(6)\nand\n38 CFR 3.309(e)\n.\nReferences\n:  For more information on\nthe addition of presumptive conditions under the provisions of\n38 CFR 3.309(e)\n, see\nM21-1, Part VIII, Subpart i, 1.B.1.i\nthe definition of IHD, see\nM21-1, Part V, Subpart iii, 5.1.a\n, and\nM21-1, Part VIII, Subpart i, 2.B.1.c\n, and\neffective dates associated with liberalizing changes of law, see\nM21-1, Part V, Subpart ii, 4.A.6\n.\nV.iii.5.1.f\n.\nConsidering Cardiovascular Conditions Subsequent to Amputation\nGrant SC on a secondary basis for the following conditions that develop subsequent to the service-connected (SC) amputation of one lower extremity at or above the knee, or SC amputations of both lower extremities at or above the ankles:\nIHD, or\nother cardiovascular disease, including hypertension.\nReferences\n:  For more information on\nproximate results or secondary conditions, see\n38 CFR 3.310(b)\nsecondary SC, see\nM21-1, Part V, Subpart ii, 2.D\n, and\nassignment of effective dates for secondary SC, see\nM21-1, Part V, Subpart ii, 4.A.3.f\n.\nV.iii.5.1.g\n.\nEffects of Rheumatic Heart Disease\nChronic rheumatic heart disease results from single or repeated attacks of rheumatic fever that produce valvular disease, manifested by\nrigidity and deformity of the cusps\nfusion of the commissures, or\nshortening and fusion of the chordae tendineae.\nThe earliest evidence of organic valvular disease is\na significant murmur, and\nhemodynamically significant valvular lesions found on x-ray, fluoroscopy, and ECG study, since these reveal the earliest stages of specific chamber enlargement.\nNote\n:  Grant SC for an aortic valve insufficiency that manifests without other cause after an in-service case of rheumatic fever.\nV.iii.5.1.h\n.\nDefinition:  Congenital Heart Defects\nCongenital heart defects\ninclude common heart conditions due to prenatal influences, such as\npatent foramen ovale\npatent ductus arteriosus\ncoarctation of the aorta, and\nintraventricular septal defect.\n2\n.\nEvaluating Diseases of the Heart\nIntroduction\nThis topic contains information about applying the evaluation criteria for diseases of the heart, including\nevaluating heart disease using metabolic equivalents (METs)\nimpact of non-service-connected (NSC) conditions on the evaluation of METs\naspirin as continuous medication\nevaluation of nephritis and cardiovascular disabilities\nevaluating arrhythmias\n, and\nconsidering co-existing heart conditions and arrhythmia\n.\nChange Date\nNovember 15, 2021\nV.iii.5.2.a\n.\nEvaluating Heart Disease Using METs\nThe General Rating Formula (GRF) for Diseases of the Heart relies on the measured or estimated workload capacity of the heart using metabolic equivalents (METs) at which symptoms of heart failure occur for the assignment of disability evaluations.\nWhen METs cannot be obtained through exercise testing for medical reasons, the examiner may provide an estimation of the METs.\nImportant\n:  The examiner must state that the estimated METs are due solely to an SC cardiovascular disability.\nReferences\n:  For more information on\nthe definition of MET, see Note 2 of the GRF for Diseases of the Heart at\n38 CFR 4.104\nsymptoms of heart failure, see Note 3 of the GRF for Diseases of the Heart at\n38 CFR 4.104\nprovisions for the application of the general rating formula for diseases of the heart, see\n38 CFR 4.100\n, and\nthe historical use of congestive heart failure and ejection fraction when evaluating diseases of the heart, see\nhistorical 38 CFR 4.104 in effect prior to November 14, 2021, and\nthe attachment\nHistorical_M21-1V_iii_5_9-15-21\n.\nV.iii.5.2.b\n.\nImpact of NSC Conditions on the Evaluation of METs\nNon-service-connected (NSC) disabilities, such as a chronic respiratory condition or morbid obesity, may have an impact on METs results.\nWhen an examiner cannot determine METs attributable to an SC cardiovascular disability due to the effects of NSC conditions and provides a sufficient rationale detailing why the determination cannot be provided, follow the guidance in\nM21-1, Part V, Subpart ii, 3.D.2.c\n.\nV.iii.5.2.c\n.\nAspirin as Continuous Medication\nAspirin is a medication that may be medically recommended for control of a cardiovascular disability such as an ischemic stroke, angina, or coronary artery bypass graft.\nWhen considering a compensable evaluation based on need for continuous medication as provided in\n38 CFR 4.100(a)\nand the GRF for evaluating diseases of the heart as provided in\n38 CFR 4.104\nfor the 10-percent evaluation, aspirin treatment must be\nmedically required\nfor care of the SC cardiovascular disorder.\nA medical professional must have advised the claimant to use aspirin to reduce disability from the SC cardiovascular disorder or to prevent additional disability from that disorder.\nA formal prescription to obtain the medication from a pharmacy is not required given that aspirin is an over-the-counter medication.\nSelf-directed or voluntary use of aspirin by a claimant who is a layperson will not be accepted as competently proving that aspirin treatment is medically necessary for treatment of the SC cardiovascular disorder.\nTo satisfy the requirement of “continuous” medication the evidence must show an ongoing regimen – not periodic, irregular use.\nTake care not to incorrectly conclude that an aspirin treatment regimen is necessary simply because aspirin appears on a current medication list.  A medication list may not contain enough information to conclude:\nwhether aspirin was medically recommended or self-prescribed\nwhether aspirin is being used for the SC cardiovascular condition or another disability, and/or\nhow frequently aspirin is being taken.\nV.iii.5.2.d\n.\nEvaluation of Nephritis and Cardiovascular Disabilities\n38 CFR 4.115\nstates that separate ratings cannot be assigned for disability from disease of the heart and any form of nephritis.\nReference\n:  For more information on the limits on separate evaluation of nephritis and cardiovascular conditions, see\nM21-1, Part V, Subpart iii, 7.2.g\n.\nV.iii.5.2.e\n.\nEvaluating Arrhythmias\nThe impairment and disability resulting from one or more types of arrhythmia, evaluated under\n38 CFR 4.104, DCs 7009-7011 and 7015\n, are essentially indistinguishable.  Consequently, assignment of multiple evaluations under any of these DCs would be in violation of\n38 CFR 4.14\n.\nAssign a single evaluation under the DC which reflects the predominant disability picture for the arrhythmia(s) in question.\nV.iii.5.2.f\n.\nConsidering Co-Existing Heart Conditions andArrhythmia\nWhen questions arise as to whether a single or separate evaluations may be assigned for co-existing cardiovascular disabilities, such as arrhythmias and other cardiovascular diseases, consider whether the criteria for evaluating the disability and/or the symptoms of the disability are separate and distinct and apply\n38 CFR 4.14\nand any other condition-specific guidance.\nWhen the evaluation criteria are separate and distinct, the symptoms do not overlap, and no specific prohibition applies, separate evaluations are warranted.\n3\n.\nRating Principles for Hypertension\n﻿\n﻿\n﻿\nIntroduction\nThis topic contains information on concepts and principles relating to hypertension, including\ndefinitions of hypertension and isolated systolic hypertension\nblood pressure readings required for SC of hypertension\n﻿\nconfirmation with multiple blood pressure readings\npre-hypertension\npredominant blood pressure in evaluations of hypertension\nlong term effects of hypertension\ngranting SC for arteriosclerotic manifestations due to hypertension\neffective dates of arteriosclerotic manifestations granted secondary to hypertension\nseparately evaluating hypertension and heart disease\nprohibition on separate evaluation of hypertension and renal dysfunction from nephritis\n, and\nevaluating rheumatic heart disease coexisting with hypertensive or arteriosclerotic heart disease\n.\nChange Date\nFebruary 5, 2024\nV.iii.5.3.a\n.\nDefinitions: Hypertension and Isolated Systolic Hypertension\nTwo types of hypertensive vascular disease are defined in\n38 CFR 4.104, DC 7101\n, Note 1.\nHypertension\nmeans elevated diastolic blood pressure is predominantly 90mm or greater.\nIsolated systolic hypertension\nmeans that systolic blood pressure is predominantly 160mm or greater with a diastolic blood pressure of less than 90mm.\nNote\n:  Use of the term “hypertension” in reports or in VA guidance will most often be used as a synonym for any type of hypertensive vascular disease.\nV.iii.5.3.b\n.\nBlood Pressure Readings Required for SC of Hypertension\nSubject to the exception below, SC for hypertensive vascular disease requires current blood pressure readings (obtained during the claim period) which meet the regulatory definition of either\nhypertension, or\nisolated systolic hypertension.\nException\n:  Current readings meeting the regulatory standards for the definitions above\nare not required\nif\nthe competent evidence shows a diagnosis of hypertension or isolated systolic hypertension, currently controlled by (or asymptomatic with) medication,\nand\na past competent diagnosis was made\nin service\nbased on manifestation of blood pressure readings to a compensable degree within the presumptive period as provided in\n38 CFR 3.307\nand\n38 CFR 3.309(a)\n, or\nsecondary to an SC disability.\nNotes\n:\nWhen SC is established based on the exception above (where current readings do not meet the regulatory definitions), the disability percentage will be either 0 percent or 10 percent, depending on whether or not the predominant diastolic pressure was 100 or more before symptoms were controlled with medication as provided in\n38 CFR 4.104, DC 7101\n.\nA disability first clearly diagnosed after service can be SC under\n38 CFR 3.303(d)\nwhen all the evidence, including that pertinent to service, establishes that the disease was incurred in service\nReference\n:  For more information on\nthe concept of competent evidence and policies on evaluating the competency of evidence, see\nM21-1, Part V, Subpart ii, 1.A\n.\nV.iii.5.3.c\n.\nConfirmation With Multiple Blood Pressure Readings\nIn addition to the definitional requirements for a diagnosis of hypertension or isolated systolic hypertension\n38 CFR 4.104, DC 7101\nprovides a second criterion that must be met for a diagnosis to be acceptable.\nSubject to the exceptions below, a diagnosis of hypertension (or isolated systolic hypertension) must be\nconfirmed by blood pressure readings taken two or more times on at least three different days\n.\nThe rulemaking for the regulation stated that the purpose of this requirement, was to “assure that the existence of hypertension is not conceded based solely on readings taken on a single, perhaps unrepresentative, day.”\nExceptions\n:\nIn a claim for reevaluation of SC hypertension, readings on multiple days are not required.  The policy, reflected in the\nHypertension\nDisability Benefits Questionnaire\n, is that where hypertension has been previously diagnosed, the examiner is only required to take three blood pressure readings on the day of examination.\nSimilarly, multiple confirmatory readings are not required when there is a past diagnosis with hypertensive vascular disease currently controlled on medication as provided in\nM21-1, Part V, Subpart iii, 5.3.b\n.\nNote 1 in\n38 CFR 4.104, DC 7101\ndoes not require\nthat a diagnosis of either type of hypertensive vascular disease\nin service treatment records\n(STRs) has been confirmed by readings taken two or more times on each of three different days for the purposes of in-service incurrence.\nImportant\n:  The decision maker must critically evaluate the evidence to ensure the in-service diagnosis was based on blood pressure readings in accordance with\n38 CFR 4.104, DC 7101\nand\nM21-1, Part V, Subpart iii, 5.3.b\nin claims for SC for hypertension where\nhypertension is currently diagnosed, and\ncontrolled with medication.\nIf the evidence is unclear, medical clarification and/or a medical opinion may be warranted.\nReferences\n:  For more information on\nevaluating evidence and making a decision, see\nM21-1, Part V, Subpart ii, 1.A\n, and\nrequesting medical examinations and medical opinions, see\nM21-1, Part IV, Subpart i, 1.A\n, and\nM21-1, Part IV, Subpart i, 2.A\n.\nV.iii.5.3.d\n.\nPre-Hypertension\nPre-hypertension\nis generally defined as systolic pressure between 120mm and 139mm and diastolic pressure from 80mm to 89mm.\nPre-hypertension is\nnot\na disability for VA purposes.\nIf the VA examination (or evidence used in lieu of a VA examination) contains only a diagnosis of pre-hypertension based on readings that do not meet the definition of hypertension or isolated systolic hypertension, do\nnot\nseek clarification, or\ngrant SC for hypertension based on the diagnosis.\nException\n:  Clarification\nmay\nbe required if a current diagnosis of “pre-hypertension” is made where readings exist in the record that meet the regulatory definition of hypertension.  This may indicate\nconflicting evidence, and/or\nequivocation by the medical professional on diagnosis or chronicity (particularly if, for example, the facts show a predominance of readings not meeting the regulatory definition of hypertension).\nReferences\n:  For more information on\nevaluating medical evidence, see\nM21-1, Part V, Subpart ii, 1.A.3\ndeveloping for additional evidence when needed, see\nM21-1, Part V, Subpart ii, 3.B.1.a\n, and\nhandling examination reports insufficient for rating purposes, see\nM21-1, Part IV, Subpart i, 3.C\n.\nV.iii.5.3.e\n.\nPredominant Blood Pressure in Evaluations of Hypertension\nEvery level of evaluation specified under\n38 CFR 4.104, DC 7101\nrequires consideration of the\npredominant\n(most common or prevailing) blood pressure. Blood pressure may fluctuate depending on a number of variables and disability evaluations must be based on valid evidence demonstrating representative disability.\nGenerally the regulation requires analysis of predominant\ncurrent\nreadings— readings from the period during which an effective date can be assigned.\nWhen current predominant blood pressure readings are non-compensable, a 10-percent evaluation may be assigned if\ncontinuous medication is required for blood pressure control, and\npast diastolic pressure (before medication was prescribed) was predominantly 100 or greater.\nImportant\n:  Do not assign a 10-percent evaluation based upon a showing of one of the two conjunctive criteria above by invoking the benefit of the doubt rule (\n38 CFR 3.102\nand\n38 CFR 4.3\nor\n38 CFR 4.7\n)\n.  When either criterion is simply not shown (for example, the claimant is using prescribed anti-hypertensive medication but diastolic pressure has never been predominantly 100 or greater) the evidence is not in relative equipoise on whether a 10-percent evaluation is appropriate and the disability picture does not more nearly approximate the 10-percent criteria.\nHowever,\n38 CFR 3.102\n,\n38 CFR 4.3\n, and\n38 CFR 4.7\nmay be applicable to whether the evidence supports each criterion, namely\nwhether diastolic readings before were predominantly 100 or higher or\nwhether continuous medication is required for control of blood pressure.\nUse the table below to assist in analyzing predominant blood pressure.\nWhen ...\nThen ...\ndetermining which diastolic or systolic pressure range is predominant\nmake note of the competent and credible evidence of diastolic and systolic readings (see\nM21-1, Part V, Subpart ii, 1.A\n)\ndetermine which readings correspond with the various levels of evaluation specified in the diagnostic criteria (for example diastolic readings “100 or more” or “110 or more”), and\nsubject to the notes below, conclude that the range with the most qualifying readings is the predominant blood pressure.\nNotes\n:\nIf there is a relative balance of readings supporting two levels of evaluation for the same time frame, apply\n38 CFR 3.102\n,\n38 CFR 4.3\nand\n38 CFR 4.7\n.\nExample\n:  If there are six diastolic measurements from one doctor in the 100 to 109 range (108, 106, 108, 104, 106, 100) in June, and six diastolic readings from another doctor in the 110 to 119 range (110, 110, 114, 110, 112, 110) the same month, give the benefit of the doubt and assign the higher 20-percent evaluation.\nIf during the evaluation period more than one blood pressure range is supported for at least a month stage the evaluation in accordance with the facts.\nExample\n:  Use the readings above but assume second doctor’s readings were taken in November. Assign a 10-percent evaluation based on the June results from the date of claim or date entitlement arose, whichever is the later; stage to 20 percent as of the date of the first readings from November.\nconsidering predominant blood pressure before control with medication\nstart with the more current of\nthe readings taken as part of the diagnostic workup period leading to the diagnosis of hypertension if medication was prescribed at that time, or\nthe readings taken as part of a subsequent diagnostic workup period leading to the prescription of medication.\nExplanation\n:  These are the readings pertinent to whether hypertensive readings were predominantly in the compensable range before hypertension was brought under control with medication.\nDo not consider\nnormal blood pressure readings taken long before the diagnosis of hypertensive vascular disease was made, or\nminimally hypertensive readings prior to active medical surveillance or observation leading to the prescription of medication.\nExplanation\n:  These are not pertinent and will impermissibly skew the analysis of the predominant blood pressure.\nconsidering a\nhistory\nof predominant blood pressure for the purposes of a 10 percent evaluation under\n38 CFR 4.104, DC 7101\nonly consider blood pressure readings obtained when the Veteran was undergoing a diagnostic evaluation for hypertension, and\ndo not consider other clinical records documenting treatment prior to the diagnostic evaluation for hypertension.\nV.iii.5.3.f\n.\nLong Term Effects of Hypertension\nHypertension may\nexist for years without causing symptoms\nso increase the cardiac load as to result in hypertrophy of the cardiac muscle or cardiac dilation and decompensation, if sufficiently severe, and\ncause arteriosclerosis of uneven distribution that often involves the vessels of one organ to a greater degree than those of the rest of the body, in cases where hypertension is long-standing.\nIf the hypertension is of sufficient degree to cause significant impairment of circulation to the organ, symptoms will manifest in accordance with the\norgan involved, and\ndegree of impairment.\nV.iii.5.3.g\n.\nGranting SC for Arteriosclerotic Manifestations Due to Hypertension\nIf additional arteriosclerotic manifestations are subsequently diagnosed in a Veteran with SC hypertension, grant SC on a secondary basis through the relationship to hypertension for any of the following:\ncerebral arteriosclerosis or thrombosis with hemiplegia\nnephrosclerosis of the kidneys with impairment of renal function, or\nmyocardial damage or coronary occlusion of the heart.\nImportant\n:  A claim for benefits is required to adjudicate a secondary SC claim for any of the arteriosclerotic manifestations.\nNotes\n:\nAddress SC for the above-listed cardiovascular conditions through the relationship to the hypertension when a sympathetic reading of the Veteran’s claim reasonably implies a claim for SC for those conditions.\nArteriosclerosis occurs with advancing age without preexisting hypertension, and may occur in some younger individuals who are predisposed to arterial changes.\nThe existence of arteriosclerosis does not imply/indicate prior hypertension.\nReferences\n:  For more information on\nsecondary SC, see\nM21-1, Part V, Subpart ii, 2.D\n, and\nsympathetic reading and scope of claim, see\nM21-1, Part V, Subpart ii, 3.A\n.\nV.iii.5.3.h\n.\nEffective Dates of Arteriosclerotic Manifestations Granted Secondary to Hypertension\nThe effective date of any grant of SC for arteriosclerotic manifestations secondary to hypertension is the date of claim or date entitlement arose, whichever is later.\nImportant\n:\nArteriosclerotic manifestations are not considered a worsening of hypertensive vascular disease (hypertension and isolated systolic hypertension) rated under\n38 CFR 4.104, DC 7101\n.  They are separate conditions which may be secondary to hypertensive vascular disease, but which nonetheless must be evaluated under rating criteria specific to their symptomology and the functions and anatomical localities they affect.  Therefore,\ndo not apply\n38 CFR 3.400(o)(2)\nto allow an effective date prior to the date of claim, as this only applies to increases.\nIf awarding SC for a disability as within scope of the hypertension claim, apply an effective date based on the date of claim for hypertension.\nReferences\n:  For more information on\nscope of claim, see\nM21-1, Part V, Subpart ii, 3.A\nsecondary SC, see\nM21-1, Part V, Subpart ii, 2.D\n, and\neffective dates, see\n38 CFR 3.400\n, and\nM21-1, Part V, Subpart ii, 4.A\n.\nV.iii.5.3.i\n.\nSeparately\nEvaluating Hypertension and Heart Disease\nEvaluate hypertension separately from hypertensive heart disease and other types of heart disease.\nEvaluate hypertension due to aortic insufficiency, which is usually the isolated systolic type, as part of the condition causing it rather than by a separate evaluation.\nNotes\n:\nThe cause of hypertension is unknown in the vast majority of cases.\nDo not establish SC for hypertension if the evidence does not contain blood pressure readings as specified in\n38 CFR 4.104, DC 7101\n, Note 1.\nV.iii.5.3.j\n.\nProhibition on Separate Evaluation of Hypertension  and Renal Dysfunction from Nephritis\n38 CFR 4.115\nprohibits assignment of separate evaluations for renal dysfunction from\nnephritis\nand for\nhypertension\nexcept\nwhere\nthe sole renal disability is absence of a kidney (even if that was due to nephritis), or\nnephritis has progressed to the point where regular dialysis is required.\nReferences\n:  For more information on\npyramiding of evaluations for nephritis and hypertension, see\nM21-1, Part V, Subpart iii, 7.2.c\nassignment of separate evaluations for nephropathy and hypertension, see\nM21-1, Part V, Subpart iii, 7.2.g\n, and\nseparating findings that constitute a single disability and the\n38 CFR 4.14\nprohibition against pyramiding, see\nM21-1, Part V, Subpart ii, 3.D.2.b\n.\nV.iii.5.3.k\n.\nEvaluating Rheumatic Heart Disease Coexisting With Hypertensive or Arteriosclerotic Heart Disease\nAccepted medical principles do\nnot\nconcede an etiological relationship between rheumatic heart disease and either hypertensive or arteriosclerotic heart disease.  Therefore, do\nnot\nextend secondary SC to systemic manifestations or arteriosclerosis in areas remote from the heart if the Veteran is SC for rheumatic heart disease.\nIf a Veteran who is SC for rheumatic heart disease develops hypertensive or arteriosclerotic heart disease after the applicable presumptive period following military discharge, request a medical opinion to determine which condition is causing the current signs and symptoms.\nNote\n:  If the examiner is unable to separate the effects of one type of heart disease from another, follow the guidance in\nM21-1, Part V, Subpart ii, 3.D.2.c\n.\n4\n.\nResiduals of Cold Injuries\nIntroduction\nThis topic contains information about residuals of cold injury, including\ngeneral effects of injury due to cold\nlong-term effects of exposure to cold\ngranting SC for residuals of cold injuries\nx-ray findings in cold injury cases\nconsidering\ncircumstances of service in cold injury cases\n, and\ncold injuries incurred during the Chosin Reservoir Campaign\n, and\ngranting SC for cold injuries incurred during the Chosin Reservoir Campaign\n.\nChange Date\nNovember 15, 2021\nV.iii.5.4.a\n.\nGeneral Effects of Injury Due to Cold\nInjury due to exposure to extremely cold temperatures causes structural and functional disturbances of\nsmall blood vessels\ncells\nnerves\nskin, and\nbone.\nThe physical effects of exposure may be acute or chronic, with immediate or latent manifestations.\nExamples\n:  Exposure to\ndamp cold temperatures (around freezing) cause frostnip and immersion or trench foot.\ndry cold, or temperatures well below freezing, cause frostbite with, in severe cases, loss of body parts, such as fingers, toes, earlobes, or the tip of the nose.\nV.iii.5.4.b\n.\nLong-Term Effects of Exposure to Cold\nThe fact that the immediate effects of cold injury may have been characterized as “\nacute”\nor “\nhealed”\ndoes not preclude development of disability at the original site of injury many years later.\nThere does not need to be continuity of symptoms following a cold injury.  Typically symptoms may last for days up to a week or two after the cold injury.  Unless there was a loss (such as part of a hand or foot), the initial injury is followed by a long symptom-free period, after which signs and symptoms may reoccur.\nAn SC cold injury is, therefore, evaluated based on those residuals identified in\n38 CFR 4.104, DC 7122\n.\nV.iii.5.4.c\n.\nGranting SC for Residuals of Cold Injuries\nGrant SC for the residuals of cold injury if\nthe cold injury was incurred during military service, and\nan intercurrent NSC cause cannot be determined.\nNotes\n:\nThe fact that an NSC systemic disease that could produce similar findings is present, or that other areas of the body not affected by cold injury have similar findings, does not necessarily preclude SC for residual conditions in the cold-injured areas.\nWhen considering the possibility of intercurrent cause, always resolve reasonable doubt in the Veteran’s favor.\nReference\n:  For more information on reasonable doubt, see\n38 CFR 3.102\n.\nV.iii.5.4.d\n.\nX-Ray Findings in Cold Injury Cases\nFor appropriate evaluation of cold injuries under the criteria of\n38 CFR 4.104, DC 7122\n, it is very important that there be medical evidence addressing whether or not x-ray abnormalities (specifically osteoporosis, subarticular punched out lesions, or osteoarthritis) exist.\nThe\nCold Injury Residuals\nDisability Benefits Questionnaire\ninstructs that the x-ray abnormalities (osteoporosis, subarticular punched out lesions, or osteoarthritis) must be confirmed by x-rays.  Once these abnormalities have been documented no further imaging studies are indicated.  This means that x-ray studies do not have to be completed on each and every subsequent examination after the specified abnormalities have been documented.\nThe DBQ asks the examiner whether x-rays have been performed and if so to provide the date of the studies.\nIf an examination is necessary for evaluation purposes, x-ray studies were not performed as part of the examination, and the specified x-ray abnormalities have not been previously documented, return the examination.\nReferences\n:  For more information on\nexamination report requirements, see\nM21-1, Part IV, Subpart i, 3.A\n, and\nhandling examinations insufficient for rating purposes, see\nM21-1, Part IV, Subpart i, 3.C\n.\nV.iii.5.4.e\n.\nConsidering Circumstances of Service in Cold Injury Cases\nConsider the circumstances of service as provided in\n38 U.S.C. 1154(a)\nand\n38 CFR 3.303(a)\n, even if STRs are not positive for a claimed cold injury.\nAlso as provided in\n38 U.S.C. 1154(b)\nand\n38 CFR 3.304(d)\n, in cases involving cold injuries related to documented combat service, satisfactory lay evidence of service conditions will be accepted if consistent with the circumstances, conditions, or hardships of combat service even if there is no official documentation in service records.\nFor example, the Battle of the Bulge (Ardennes/Rhineland) in the winter of 1944/1945 during World War II was known for its extreme cold.  If participation in the Battle of the Bulge is confirmed by the\nDD\nForm 214, Certificate of Release or Discharge from Active Duty\n, or personnel records, concede exposure to extreme cold.  If the Veteran engaged in combat with the enemy and the circumstances of service are consistent with claimed service in the Battle of the Bulge, concede exposure to extreme cold.\nAfford an examination if the circumstances are consistent with exposure to extreme cold, proving an event in service, and the criteria for a necessary examination are otherwise met.\nReference\n:  For more information on determining whether an examination is necessary, see\n38 CFR 3.159(c)(4)\n, and\nM21-1, Part IV, Subpart i, 1.A\nand\nB\n.\nV.iii.5.4.f\n.\nConsidering Cold Injuries Incurred During the Chosin Reservoir Campaign\nThe Chosin Reservoir Campaign was conducted during the Korean War, October 1950 through December 1950, in temperatures of –20ºF or lower.  Many participants in this campaign suffered from frostbite for which they received no treatment and, as a result, there may be no STRs to directly support their claims for frostbite.\nIf the Veteran’s participation in the Chosin Reservoir Campaign is confirmed, concede exposure to extreme cold under the provisions of\n38 U.S.C. 1154(a)\n.\nV.iii.5.4.g\n.\nGranting SC for Cold Injuries Incurred During the Chosin Reservoir Campaign\nGrant SC under the provisions of\n38 CFR 3.303(a)\nand\n38 CFR 3.304(d)\nif\nthe Veteran has a disability which is diagnosed as a residual of cold injury, and\nthere are no other circumstances to which this disability may be attributed.\n5\n.\nOther Cardiovascular Disabilities\nIntroduction\nThis topic contains information about other cardiovascular disabilities, including\nevaluating Raynaud’s syndrome and Raynaud’s disease\ntesting requirements for peripheral arterial disease\n, and\nchanges in the rating schedule for the cardiovascular system\n.\nChange Date\nFebruary 5, 2024\nV.iii.5.5.a\n.\nEvaluating Raynaud’s Syndrome and Raynaud’s Disease\nRaynaud’s syndrome and Raynaud’s disease are unrelated in etiology and severity.  Raynaud’s disease is more common and tends to be less severe than Raynaud’s syndrome.\nRaynaud’s syndrome (also known as secondary Raynaud’s phenomenon) is typically caused by autoimmune diseases such as scleroderma, lupus, rheumatoid arthritis, atherosclerosis, or polycythemia.  This condition is rated under\n38 CFR 4.104, DC 7117\n.\nRaynaud’s disease (also known as primary Raynaud’s phenomenon) is idiopathic (due to an unknown cause).  This condition is rated under\n38 CFR 4.104, DC 7124\n.\nNote\n:  A Veteran cannot receive simultaneous ratings under both\n38 CFR 4.104, DC 7117 and DC 7124\nbecause Raynaud’s disease and Raynaud’s syndrome cannot be comorbid conditions.\nV.iii.5.5.b\n.\nTesting Requirements for Peripheral Arterial Disease\nUnder\n38 CFR 4.104, DC 7114, Note 2\n, peripheral arterial disease may be evaluated utilizing ankle brachial index, ankle pressure, toe pressure, or transcutaneous oxygen tension values.\nThe ankle/brachial index is the most common type of testing for evaluating peripheral arterial disease.  In some situations, ankle/brachial index measurement is not appropriate for a given disability.  In those cases, ankle pressure, toe pressure, or transcutaneous oxygen tension values are more appropriate tests.\nIf the ankle pressure, toe pressure, and/or transcutaneous oxygen tension measurements are not of record, evaluate based on the ankle/brachial index unless the examiner indicates that one of the other tests is necessary.\nIf more than one test result is available, evaluate using the test result that results in the highest evaluation.\nV.iii.5.5.c\n.\nChanges in the Rating Schedule for the Cardiovascular System\nThe rating criteria for cardiovascular conditions have undergone historical changes.  Recent full-scale historical revisions were effective on the following dates:\nNovember 14, 2021, and\nJanuary 12, 1998.\nNotes\n:\nThese changes in the rating criteria\nare not considered liberalizing, and\nshould not be the basis for a reduction in disability rating unless medical evidence establishes that the disability has actually improved.\nA regulatory change to\n38 CFR 4.104, DC 7122\neffective August 13, 1998, further revised, but did not substantively change, the evaluation criteria of long-term effects of cold injury residuals.\nReferences\n:  For more information on\nrevised rating schedule criteria and effective dates, see\nM21-1, Part V, Subpart ii, 4.A.6\n, and\nevaluating disabilities following rating schedule readjustment, see\nM21-1, Part V, Subpart ii, 3.D.2\n.\n﻿﻿\n<-- Previous Section\nNext Section -->\nTo Top",
  "content_html": "<div class=\"article-content\">\n<div compile-custom=\"article.content\" ng-aria=\"articleContent\"><p class=\"ng-scope\"></p><p class=\"ng-scope\" style=\"text-align: right\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 11px\">﻿﻿<a articleid=\"554400000180881\" articlename=\"M21-1, Part V, Subpart iii, Chapter 4, Section B - Tuberculosis\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180881/M21-1-Part-V-Subpart-iii-Chapter-4-Section-B-Tuberculosis\">&lt;-- Previous Section</a>  <a articleid=\"554400000014523\" articlename=\"M21-1, Part V, Subpart iii, Chapter 6 - Digestive Disabilities\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000014523/M21-1-Part-V-Subpart-iii-Chapter-6-Digestive-Disabilities\">Next Section --&gt;</a></span></span></p><h2 class=\"ng-scope\"><a id=\"top\" name=\"top\"><span style=\"font-size: 16px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span>Overview</span></span></span></a></h2><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><div><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">In This Chapter</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">This chapter contains the following topics:</span></span></div><div></div><div><table border=\"1\" cellpadding=\"1\" cellspacing=\"1\" style=\"border-spacing: 1px; border-collapse: revert;\" summary=\"Column 1 has the topic number and column 2 has the topic title.\"><thead><tr><th scope=\"col\" style=\"width: 86px; padding: 1px;\"><div style=\"text-align: center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Topic</strong></span></span></span></span></div></th><th scope=\"col\" style=\"width: 423px; padding: 1px;\"><div style=\"text-align: center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Topic Name</strong></span></span></span></span></div></th></tr></thead><tbody><tr><td style=\"width: 86px; padding: 1px;\"><div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">1 </span></span></span></span></div></td><td style=\"width: 423px; padding: 1px;\"><div><a href=\"#1\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Rating Principles for Heart Conditions</span></span></span></span></a></div></td></tr><tr><td style=\"width: 86px; padding: 1px;\"><div style=\"text-align: center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">2</span></span></div></td><td style=\"width: 423px; padding: 1px;\"><div><a href=\"#2\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Evaluating Diseases of the Heart</span></span></a></div></td></tr><tr><td style=\"width: 86px; padding: 1px;\"><div style=\"text-align: center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">3</span></span></div></td><td style=\"width: 423px; padding: 1px;\"><div><a href=\"#3\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Rating Principles for Hypertension</span></span></a></div></td></tr><tr><td style=\"width: 86px; padding: 1px;\"><div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">4</span></span></span></span></div></td><td style=\"width: 423px; padding: 1px;\"><div><a href=\"#4\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Residuals of Cold Injuries</span></span></span></span></a></div></td></tr><tr><td style=\"width: 86px; text-align: center; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">5</span></span></div></td><td style=\"width: 423px; padding: 1px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><a href=\"#5\" target=\"_self\">Other Cardiovascular Disabilities</a></span></span></div></td></tr></tbody></table></div><div></div></td></tr></tbody></table><div class=\"ng-scope\"><div style=\"margin-left: 85pt\"><hr/></div><p> <br/> </p></div><h2 class=\"ng-scope\"> <span style=\"font-size: 16px\"><span style=\"font-family: arial, helvetica, sans-serif\">1<a id=\"1\" name=\"1\">.</a>  Rating Principles for Heart Conditions</span></span></h2><div class=\"ng-scope\"> <br/> </div><div class=\"ng-scope\"></div><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Introduction</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">This topic contains miscellaneous cardiovascular concepts and principles, including</span></span></div><ul><li><div><a href=\"#1a\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">definition of arteriosclerotic heart disease</span></span></a></div></li><li><div><a href=\"#1b\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">documentation required to support a diagnosis of arteriosclerotic heart disease</span></span></a></div></li><li><div><a href=\"#1c\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">manifestations of advanced arteriosclerotic disease in service</span></span></a></div></li><li><div><a href=\"#1d\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">documentation of myocardial infarction (MI)</span></span></a></div></li><li><div><a href=\"#1e\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">effective dates and liberalizing changes affecting service connection (SC) for ischemic heart disease (IHD)</span></span></a></div></li><li><div><a href=\"#1f\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">considering cardiovascular conditions subsequent to amputation</span></span></a></div></li><li><div><a href=\"#1g\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">effects of rheumatic heart disease</span></span></a><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">, and</span></span></div></li><li><div><a href=\"#1h\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">definition of congenital heart defects.</span></span></a></div></li></ul></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Change Date</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">February 5, 2024</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">V.iii.5.1.a<a id=\"1a\" name=\"1a\">.</a>  Definition:  Arteriosclerotic Heart Disease</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><strong><em>Arteriosclerotic heart disease</em></strong>, also diagnosed as ischemic heart disease (IHD) and coronary artery disease (CAD), is a disease of the heart caused by the diminution of blood supply to the heart muscle due to narrowing of the cavity of one or both coronary arteries due to the accumulation of fatty material on the inner lining of the arterial wall.</span></span></div><div></div><div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><em><strong>Note</strong></em>:  IHD refers only to heart disease, and therefore, does not include hypertension or peripheral manifestations of arteriosclerosis such as peripheral vascular disease or stroke.  Consider presumptive service connection (SC) for IHD under <a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-3/subpart-A/subject-group-ECFR39056aee4e9ff13/section-3.309\" target=\"_blank\">38 CFR 3.309(e)</a>.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><em><strong>Reference</strong></em>:  For more information on the definition of IHD, see </span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-3/subpart-A/subject-group-ECFR39056aee4e9ff13/section-3.309\" target=\"_blank\">38 CFR 3.309(e)</a>, and</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><a articleid=\"554400000177426\" articlename=\"M21-1, Part VIII, Subpart i, Chapter 2, Section B - Determining Eligibility to Retroactive Payment Under the Nehmer Stipulation\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177426/M21-1-Part-VIII-Subpart-i-Chapter-2-Section-B-Determining-Eligibility-to-Retroactive-Payment-Under-the-Nehmer-Stipulation\">M21-1, Part VIII, Subpart i, 2.B.1.c</a>.</span></span></li></ul></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">V.iii.5.1.b<a id=\"1b\" name=\"1b\">.</a>  Documentation Required to Support a Diagnosis of Arteriosclerotic Heart Disease</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">For rating purposes, a diagnosis of arteriosclerotic heart disease must be documented by objective testing.  Objective tests include, but are not limited to</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">electrocardiogram (ECG or EKG) findings</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">treadmill exercise testing (with or without a thallium scan),or</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">cardiac catheterization and angiography. </span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><strong><em>Note</em></strong>:  The actual test results <em>do not</em> need to be of record if the evidence indicates that the diagnosis was rendered by a competent medical professional <em>and</em> based on the results of an objective test.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><strong><em>Important</em></strong>:  Symptoms of chest pain alone are <strong><em>not</em></strong> sufficient to support a clinical diagnosis of arteriosclerotic heart disease for rating purposes.  As chest pain is a symptom of multiple disabilities, the diagnosis of arteriosclerotic heart disease <em>must</em> be supported with objective documentation.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">V.iii.5.1.c<a id=\"1c\" name=\"1c\">.</a>  Manifestations of Advanced Arteriosclerotic Disease in Service</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">When SC for a cardiovascular condition is claimed, the mere identification of arteriosclerotic disease upon routine examination early in service is <em>not</em> a basis for SC.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Manifestation of lesions or symptoms of chronic disease will establish pre-service existence under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=8c8c1718ddbc2174459adeeef00bc703&amp;node=se38.1.3_1303&amp;rgn=div8\" target=\"_blank\">38 CFR 3.303(c)</a> if objective evidence shows manifestation</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">from date of enlistment, or</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">so close to enlistment that chronic disease could not have originated during service. </span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><strong><em>Important</em></strong>:</span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">An analysis of the presumption of soundness under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=8c8c1718ddbc2174459adeeef00bc703&amp;node=se38.1.3_1304&amp;rgn=div8\" target=\"_blank\">38 CFR 3.304</a> and the provisions on aggravation under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=8c8c1718ddbc2174459adeeef00bc703&amp;node=se38.1.3_1306&amp;rgn=div8\" target=\"_blank\">38 CFR 3.306</a> may be required.</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Grant SC for any sudden development during service of coronary occlusion or thrombosis whether or not these are manifestations of advanced long-standing arteriosclerotic disease. </span></span></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><strong><em>Note</em></strong>:  Under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=8c8c1718ddbc2174459adeeef00bc703&amp;node=se38.1.3_16&amp;rgn=div8\" target=\"_blank\">38 CFR 3.6(a)</a>, inactive duty for training qualifies as active service if an individual becomes disabled or dies from an acute myocardial infarction (MI), a cardiac arrest, or a cerebrovascular accident occurring during such training.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">V.iii.5.1.d<a id=\"1d\" name=\"1d\">.</a>  Documentation of MI</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=ce8e46cb71688f26d85a16832bd8cdf0&amp;mc=true&amp;node=se38.1.4_1104&amp;rgn=div8\" target=\"_blank\">38 CFR 4.104, diagnostic code (DC) 7006</a> requires documentation of an MI by laboratory tests.  Health providers may rely on a variety of diagnostic tests to document MI.  </span></span></div><div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Testing may include, but is not limited to,</span></span><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">EKG</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">cardiac enzymes (Troponin, CKMB), and</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">radionuclide imaging. </span></span></li></ul></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">The <em>Heart Conditions Disability Benefits Questionnaire</em> (DBQ) elicits information about testing conducted in support of cardiac workup. </span></span></li></ul></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">If an assessment of an MI appears to have been made without diagnostic testing or if there is a question about whether the assessment was supported by appropriate testing, obtain clarification from the Department of Veterans Affairs (VA) examiner or other provider. </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><strong><em>Reference</em></strong>:  For more information on evaluating medical evidence, see <a articleid=\"554400000014383\" articlename=\"M21-1, Part V, Subpart ii, Chapter 1, Section A - Principles of Reviewing and Weighing Evidence\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000014383/M21-1-Part-V-Subpart-ii-Chapter-1-Section-A-Principles-of-Reviewing-and-Weighing-Evidence\">M21-1, Part V, Subpart ii, 1.A.3</a>.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">V.iii.5.1.e<a id=\"1e\" name=\"1e\">.</a><strong>  Effective Dates and Liberalizing Changes Affecting SC for IHD</strong></span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">IHD became a condition presumptively associated with herbicide exposure effective August 31, 2010.  This was a liberalizing change of law.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Therefore, unless an earlier effective date is available under the provisions of <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=730552af9f371c1ffbf4acea2daa806b&amp;node=se38.1.3_1816&amp;rgn=div8\" target=\"_blank\">38 CFR 3.816</a>, consider the application of <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=055c1bf4970910e4b257cfd824ce0b59&amp;node=se38.1.3_1114&amp;rgn=div8\" target=\"_blank\">38 CFR 3.114(a)</a> when granting presumptive SC for IHD related to herbicide exposure under the provisions of <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=8c8c1718ddbc2174459adeeef00bc703&amp;node=se38.1.3_1307&amp;rgn=div8\" target=\"_blank\">38 CFR 3.307(a)(6)</a> and <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=8c8c1718ddbc2174459adeeef00bc703&amp;node=se38.1.3_1309&amp;rgn=div8\" target=\"_blank\">38 CFR 3.309(e)</a>.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><strong><em>References</em></strong>:  For more information on</span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">the addition of presumptive conditions under the provisions of <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=8c8c1718ddbc2174459adeeef00bc703&amp;node=se38.1.3_1309&amp;rgn=div8\" target=\"_blank\">38 CFR 3.309(e)</a>, see <a articleid=\"554400000177423\" articlename=\"M21-1, Part VIII, Subpart i, Chapter 1, Section B - Ratings for Disabilities Associated with Herbicide Exposure\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177423/M21-1-Part-VIII-Subpart-i-Chapter-1-Section-B-Ratings-for-Disabilities-Associated-with-Herbicide-Exposure\">M21-1, Part VIII, Subpart i, 1.B.1.i</a></span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">the definition of IHD, see </span></span><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><a href=\"#1a\" target=\"_self\">M21-1, Part V, Subpart iii, 5.1.a</a>, and</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><a articleid=\"554400000177426\" articlename=\"M21-1, Part VIII, Subpart i, Chapter 2, Section B - Determining Eligibility to Retroactive Payment Under the Nehmer Stipulation\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177426/M21-1-Part-VIII-Subpart-i-Chapter-2-Section-B-Determining-Eligibility-to-Retroactive-Payment-Under-the-Nehmer-Stipulation\">M21-1, Part VIII, Subpart i, 2.B.1.c</a>, and</span></span></li></ul></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">effective dates associated with liberalizing changes of law, see <a articleid=\"554400000180492\" articlename=\"M21-1, Part V, Subpart ii, Chapter 4, Section A - Effective Dates\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180492/M21-1-Part-V-Subpart-ii-Chapter-4-Section-A-Effective-Dates\">M21-1, Part V, Subpart ii, 4.A.6</a>.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">V.iii.5.1.f<a id=\"1f\" name=\"1f\">.</a>  Considering Cardiovascular Conditions Subsequent to Amputation</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Grant SC on a secondary basis for the following conditions that develop subsequent to the service-connected (SC) amputation of one lower extremity at or above the knee, or SC amputations of both lower extremities at or above the ankles:</span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">IHD, or</span></span></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">other cardiovascular disease, including hypertension. </span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><strong><em>References</em></strong>:  For more information on</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">proximate results or secondary conditions, see <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=8c8c1718ddbc2174459adeeef00bc703&amp;node=se38.1.3_1310&amp;rgn=div8\" target=\"_blank\">38 CFR 3.310(b)</a></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">secondary SC, see <a articleid=\"554400000180484\" articlename=\"M21-1, Part V, Subpart ii, Chapter 2, Section D - Secondary Service Connection (SC) and Aggravation of Non-Service-Connected (NSC) Disabilities\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180484/M21-1-Part-V-Subpart-ii-Chapter-2-Section-D-Secondary-Service-Connection-SC-and-Aggravation-of-Non-Service-Connected-NSC-Disabilities\">M21-1, Part V, Subpart ii, 2.D</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">assignment of effective dates for secondary SC, see <a articleid=\"554400000180492\" articlename=\"M21-1, Part V, Subpart ii, Chapter 4, Section A - Effective Dates\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180492/M21-1-Part-V-Subpart-ii-Chapter-4-Section-A-Effective-Dates\">M21-1, Part V, Subpart ii, 4.A.3.f</a>.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">V.iii.5.1.g<a id=\"1g\" name=\"1g\">.</a>  Effects of Rheumatic Heart Disease</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Chronic rheumatic heart disease results from single or repeated attacks of rheumatic fever that produce valvular disease, manifested by</span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">rigidity and deformity of the cusps</span></span></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">fusion of the commissures, or</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">shortening and fusion of the chordae tendineae. </span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">The earliest evidence of organic valvular disease is</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">a significant murmur, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">hemodynamically significant valvular lesions found on x-ray, fluoroscopy, and ECG study, since these reveal the earliest stages of specific chamber enlargement. </span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><strong><em>Note</em></strong>:  Grant SC for an aortic valve insufficiency that manifests without other cause after an in-service case of rheumatic fever.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">V.iii.5.1.h<a id=\"1h\" name=\"1h\">.</a>  Definition:  Congenital Heart Defects</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><strong><em>Congenital heart defects</em></strong> include common heart conditions due to prenatal influences, such as</span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">patent foramen ovale</span></span></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">patent ductus arteriosus</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">coarctation of the aorta, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">intraventricular septal defect.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><div class=\"ng-scope\"> <br/> </div><h2 class=\"ng-scope\"> <strong><span style=\"font-size: 16px\"><span style=\"font-family: arial, helvetica, sans-serif\">2<a id=\"2\" name=\"2\">.</a>  Evaluating Diseases of the Heart</span></span></strong></h2><div class=\"ng-scope\"></div><div class=\"ng-scope\"></div><div class=\"ng-scope\"></div><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Introduction</strong></span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">This topic contains information about applying the evaluation criteria for diseases of the heart, including</span></span><ul><li><a href=\"#2a\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">evaluating heart disease using metabolic equivalents (METs)</span></span></a></li><li><a href=\"#2b\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">impact of non-service-connected (NSC) conditions on the evaluation of METs</span></span></a></li><li><a href=\"#2c\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">aspirin as continuous medication</span></span></a></li><li><a href=\"#2d\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">evaluation of nephritis and cardiovascular disabilities</span></span></a></li><li><a href=\"#2e\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">evaluating arrhythmias</span></span></a><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">, and</span></span></li><li><a href=\"#2f\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">considering co-existing heart conditions and arrhythmia</span></span></a><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">.</span></span></li></ul></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Change Date</strong></span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">November 15, 2021</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">V.iii.5.2.a<a id=\"2a\" name=\"2a\">.</a>  Evaluating Heart Disease Using METs</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">The General Rating Formula (GRF) for Diseases of the Heart relies on the measured or estimated workload capacity of the heart using metabolic equivalents (METs) at which symptoms of heart failure occur for the assignment of disability evaluations.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">When METs cannot be obtained through exercise testing for medical reasons, the examiner may provide an estimation of the METs.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><strong><em>Important</em></strong>:  The examiner must state that the estimated METs are due solely to an SC cardiovascular disability.</span></span></div><div></div><div><div><span style=\"font-family: Arial, Helvetica, sans-serif\"><span style=\"font-size: 14px\"><b><i>References</i></b>:  For more information on</span></span></div><ul><li><span style=\"font-family: Arial, Helvetica, sans-serif\"><span style=\"font-size: 14px\">the definition of MET, see Note 2 of the GRF for Diseases of the Heart at <a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-B/subject-group-ECFRc88f57fafb24f86/section-4.104\" target=\"_blank\">38 CFR 4.104</a></span></span></li><li><span style=\"font-family: Arial, Helvetica, sans-serif\"><span style=\"font-size: 14px\">symptoms of heart failure, see Note 3 of the GRF for Diseases of the Heart at <a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-B/subject-group-ECFRc88f57fafb24f86/section-4.104\" target=\"_blank\">38 CFR 4.104</a></span></span></li><li><span style=\"font-family: Arial, Helvetica, sans-serif\"><span style=\"font-size: 14px\">provisions for the application of the general rating formula for diseases of the heart, see <a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-B/subject-group-ECFRc88f57fafb24f86/section-4.100\" target=\"_blank\">38 CFR 4.100</a>, and</span></span></li><li><span style=\"font-family: Arial, Helvetica, sans-serif\"><span style=\"font-size: 14px\">the historical use of congestive heart failure and ejection fraction when evaluating diseases of the heart, see</span></span><ul><li><span style=\"font-family: Arial, Helvetica, sans-serif\"><span style=\"font-size: 14px\">historical 38 CFR 4.104 in effect prior to November 14, 2021, and</span></span></li><li><span style=\"font-family: Arial, Helvetica, sans-serif\"><span style=\"font-size: 14px\">the attachment <i>Historical_M21-1V_iii_5_9-15-21</i>.  </span></span></li></ul></li></ul></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">V.iii.5.2.b<a id=\"2b\" name=\"2b\">.</a>  Impact of NSC Conditions on the Evaluation of METs </span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Non-service-connected (NSC) disabilities, such as a chronic respiratory condition or morbid obesity, may have an impact on METs results.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">When an examiner cannot determine METs attributable to an SC cardiovascular disability due to the effects of NSC conditions and provides a sufficient rationale detailing why the determination cannot be provided, follow the guidance in <a articleid=\"554400000180489\" articlename=\"M21-1, Part V, Subpart ii, Chapter 3, Section D - Evaluating Disabilities\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180489/M21-1-Part-V-Subpart-ii-Chapter-3-Section-D-Evaluating-Disabilities\">M21-1, Part V, Subpart ii, 3.D.2.c</a>.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">V.iii.5.2.c<a id=\"2c\" name=\"2c\">.</a>  Aspirin as Continuous Medication</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Aspirin is a medication that may be medically recommended for control of a cardiovascular disability such as an ischemic stroke, angina, or coronary artery bypass graft.  </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">When considering a compensable evaluation based on need for continuous medication as provided in <a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-B/subject-group-ECFRc88f57fafb24f86/section-4.100\" target=\"_blank\">38 CFR 4.100(a)</a> and the GRF for evaluating diseases of the heart as provided in <a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-B/subject-group-ECFRc88f57fafb24f86/section-4.104\" target=\"_blank\">38 CFR 4.104</a> for the 10-percent evaluation, aspirin treatment must be <i>medically required</i> for care of the SC cardiovascular disorder.  </span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">A medical professional must have advised the claimant to use aspirin to reduce disability from the SC cardiovascular disorder or to prevent additional disability from that disorder. </span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">A formal prescription to obtain the medication from a pharmacy is not required given that aspirin is an over-the-counter medication.</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Self-directed or voluntary use of aspirin by a claimant who is a layperson will not be accepted as competently proving that aspirin treatment is medically necessary for treatment of the SC cardiovascular disorder. </span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">To satisfy the requirement of “continuous” medication the evidence must show an ongoing regimen – not periodic, irregular use.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Take care not to incorrectly conclude that an aspirin treatment regimen is necessary simply because aspirin appears on a current medication list.  A medication list may not contain enough information to conclude:</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">whether aspirin was medically recommended or self-prescribed</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">whether aspirin is being used for the SC cardiovascular condition or another disability, and/or</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">how frequently aspirin is being taken. </span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">V.iii.5.2.d<a id=\"2d\" name=\"2d\">.</a>  Evaluation of Nephritis and Cardiovascular Disabilities</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=aa6453d39e01ace124f6a68c2af719c9&amp;mc=true&amp;node=se38.1.4_1115&amp;rgn=div8\" target=\"_blank\">38 CFR 4.115</a> states that separate ratings cannot be assigned for disability from disease of the heart and any form of nephritis. </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><em><strong>Reference</strong></em>:  For more information on the limits on separate evaluation of nephritis and cardiovascular conditions, see <a articleid=\"554400000180593\" articlename=\"M21-1, Part V, Subpart iii, Chapter 7 - Genitourinary Disabilities\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180593/M21-1-Part-V-Subpart-iii-Chapter-7-Genitourinary-Disabilities\">M21-1, Part V, Subpart iii, 7.2.g</a>.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">V.iii.5.2.e<a id=\"2e\" name=\"2e\">.</a>  Evaluating Arrhythmias</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><span style=\"tab-stops: 6.5in\">The impairment and disability resulting from one or more types of arrhythmia, evaluated under <a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-B/subject-group-ECFRc88f57fafb24f86/section-4.104\" target=\"_blank\">38 CFR 4.104, DCs 7009-7011 and 7015</a>, are essentially indistinguishable.  Consequently, assignment of multiple evaluations under any of these DCs would be in violation of <a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-A/section-4.14\" target=\"_blank\">38 CFR 4.14</a>.  </span></span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Assign a single evaluation under the DC which reflects the predominant disability picture for the arrhythmia(s) in question.  </span></span></div></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><strong><strong>V.iii.5.2.f</strong><a id=\"2f\" name=\"2f\">.</a>  Considering Co-Existing Heart Conditions andArrhythmia</strong></span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">When questions arise as to whether a single or separate evaluations may be assigned for co-existing cardiovascular disabilities, such as arrhythmias and other cardiovascular diseases, consider whether the criteria for evaluating the disability and/or the symptoms of the disability are separate and distinct and apply <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=d05d5d2e780aa4261e1a7e8fe538e0ab&amp;mc=true&amp;node=se38.1.4_114&amp;rgn=div8\" target=\"_blank\">38 CFR 4.14</a> and any other condition-specific guidance.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">When the evaluation criteria are separate and distinct, the symptoms do not overlap, and no specific prohibition applies, separate evaluations are warranted. </span></span></div></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><div class=\"ng-scope\" style=\"margin-left: 85pt\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span><br/> </div><div class=\"ng-scope\"></div><h2 class=\"ng-scope\"><strong><span style=\"font-size: 16px\"><span style=\"font-family: arial , helvetica , sans-serif\">3<a id=\"3\" name=\"3\">.</a>  Rating Principles for Hypertension<span>﻿</span><span>﻿</span><span>﻿</span></span></span></strong></h2><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><div><p><br/><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></p><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Introduction</span></span></strong></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">This topic contains information on concepts and principles relating to hypertension, including</span></span></div><ul><li><div><a href=\"#3a\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">definitions of hypertension and isolated systolic hypertension</span></span></a></div></li><li><div><a href=\"#3b\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">blood pressure readings required for SC of hypertension</span></span></a><span>﻿</span></div></li><li><div><a href=\"#3c\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">confirmation with multiple blood pressure readings</span></span></a></div></li><li><div><a href=\"#3d\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">pre-hypertension</span></span></a></div></li><li><div><a href=\"#3e\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">predominant blood pressure in evaluations of hypertension</span></span></a></div></li><li><div><a href=\"#3f\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">long term effects of hypertension</span></span></a></div></li><li><div><a href=\"#3g\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">granting SC for arteriosclerotic manifestations due to hypertension</span></span></a></div></li><li><div><a href=\"#3h\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">effective dates of arteriosclerotic manifestations granted secondary to hypertension</span></span></a></div></li><li><div><a href=\"#3i\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">separately evaluating hypertension and heart disease</span></span></a></div></li><li><div><a href=\"#3j\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">prohibition on separate evaluation of hypertension and renal dysfunction from nephritis</span></span></a><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">, and</span></span></div></li><li><div><a href=\"#3k\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">evaluating rheumatic heart disease coexisting with hypertensive or arteriosclerotic heart disease</span></span></a><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><div><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><strong><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Change Date</span></span></strong></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">February 5, 2024</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><div><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><strong><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">V.iii.5.3.a<a id=\"3a\" name=\"3a\">.</a>  Definitions: Hypertension and Isolated Systolic Hypertension</span></span></strong></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Two types of hypertensive vascular disease are defined in <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=35b52ec77cd5f89200838792a366496d&amp;node=se38.1.4_1104&amp;rgn=div8\" target=\"_blank\">38 CFR 4.104, DC 7101</a>, Note 1.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><strong><em>Hypertension</em></strong> means elevated diastolic blood pressure is predominantly 90mm or greater. </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><strong><em>Isolated systolic hypertension</em></strong> means that systolic blood pressure is predominantly 160mm or greater with a diastolic blood pressure of less than 90mm.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><strong><em>Note</em></strong>:  Use of the term “hypertension” in reports or in VA guidance will most often be used as a synonym for any type of hypertensive vascular disease. </span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><div><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">V.iii.5.3.b<a id=\"3b\" name=\"3b\">.</a>  Blood Pressure Readings Required for SC of Hypertension</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Subject to the exception below, SC for hypertensive vascular disease requires current blood pressure readings (obtained during the claim period) which meet the regulatory definition of either</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">hypertension, or</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">isolated systolic hypertension. </span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><strong><em>Exception</em></strong>:  Current readings meeting the regulatory standards for the definitions above <em>are not required</em> if</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">the competent evidence shows a diagnosis of hypertension or isolated systolic hypertension, currently controlled by (or asymptomatic with) medication, <em>and</em></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">a past competent diagnosis was made</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">in service</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">based on manifestation of blood pressure readings to a compensable degree within the presumptive period as provided in <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=8c8c1718ddbc2174459adeeef00bc703&amp;node=se38.1.3_1307&amp;rgn=div8\" target=\"_blank\">38 CFR 3.307</a> and <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=8c8c1718ddbc2174459adeeef00bc703&amp;node=se38.1.3_1309&amp;rgn=div8\" target=\"_blank\">38 CFR 3.309(a)</a>, or</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">secondary to an SC disability.  </span></span></div></li></ul></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><strong><em>Notes</em></strong>:  </span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">When SC is established based on the exception above (where current readings do not meet the regulatory definitions), the disability percentage will be either 0 percent or 10 percent, depending on whether or not the predominant diastolic pressure was 100 or more before symptoms were controlled with medication as provided in <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=35b52ec77cd5f89200838792a366496d&amp;node=se38.1.4_1104&amp;rgn=div8\" target=\"_blank\">38 CFR 4.104, DC 7101</a>.</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">A disability first clearly diagnosed after service can be SC under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=8c8c1718ddbc2174459adeeef00bc703&amp;node=se38.1.3_1303&amp;rgn=div8\" target=\"_blank\">38 CFR 3.303(d)</a> when all the evidence, including that pertinent to service, establishes that the disease was incurred in service</span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"> <strong><em>Reference</em></strong>:  For more information on</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">the concept of competent evidence and policies on evaluating the competency of evidence, see <a articleid=\"554400000014383\" articlename=\"M21-1, Part V, Subpart ii, Chapter 1, Section A - Principles of Reviewing and Weighing Evidence\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000014383/M21-1-Part-V-Subpart-ii-Chapter-1-Section-A-Principles-of-Reviewing-and-Weighing-Evidence\">M21-1, Part V, Subpart ii, 1.A</a>.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><div><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">V.iii.5.3.c<a id=\"3c\" name=\"3c\">.</a>  Confirmation With Multiple Blood Pressure Readings</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">In addition to the definitional requirements for a diagnosis of hypertension or isolated systolic hypertension <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=35b52ec77cd5f89200838792a366496d&amp;node=se38.1.4_1104&amp;rgn=div8\" target=\"_blank\">38 CFR 4.104, DC 7101</a>  provides a second criterion that must be met for a diagnosis to be acceptable.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Subject to the exceptions below, a diagnosis of hypertension (or isolated systolic hypertension) must be <strong><em>confirmed by blood pressure readings taken two or more times on at least three different days</em></strong>.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">The rulemaking for the regulation stated that the purpose of this requirement, was to “assure that the existence of hypertension is not conceded based solely on readings taken on a single, perhaps unrepresentative, day.”</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><strong><em>Exceptions</em></strong>: </span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">In a claim for reevaluation of SC hypertension, readings on multiple days are not required.  The policy, reflected in the <em>Hypertension</em> <em>Disability Benefits Questionnaire</em>, is that where hypertension has been previously diagnosed, the examiner is only required to take three blood pressure readings on the day of examination. </span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Similarly, multiple confirmatory readings are not required when there is a past diagnosis with hypertensive vascular disease currently controlled on medication as provided in <a href=\"#3b\" target=\"_self\">M21-1, Part V, Subpart iii, 5.3.b</a>. </span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Note 1 in <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=35b52ec77cd5f89200838792a366496d&amp;node=se38.1.4_1104&amp;rgn=div8\" target=\"_blank\">38 CFR 4.104, DC 7101</a><em> does not require</em> that a diagnosis of either type of hypertensive vascular disease <em>in service treatment records </em>(STRs) has been confirmed by readings taken two or more times on each of three different days for the purposes of in-service incurrence.  </span></span></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><strong><em>Important</em></strong>:  The decision maker must critically evaluate the evidence to ensure the in-service diagnosis was based on blood pressure readings in accordance with <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=35b52ec77cd5f89200838792a366496d&amp;node=se38.1.4_1104&amp;rgn=div8\" target=\"_blank\">38 CFR 4.104, DC 7101</a> and <a href=\"#3b\" target=\"_self\">M21-1, Part V, Subpart iii, 5.3.b</a> in claims for SC for hypertension where</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">hypertension is currently diagnosed, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">controlled with medication. </span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">If the evidence is unclear, medical clarification and/or a medical opinion may be warranted.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><strong><em>References</em></strong>:  For more information on</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">evaluating evidence and making a decision, see <a articleid=\"554400000014383\" articlename=\"M21-1, Part V, Subpart ii, Chapter 1, Section A - Principles of Reviewing and Weighing Evidence\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000014383/M21-1-Part-V-Subpart-ii-Chapter-1-Section-A-Principles-of-Reviewing-and-Weighing-Evidence\">M21-1, Part V, Subpart ii, 1.A</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">requesting medical examinations and medical opinions, see </span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><a articleid=\"554400000180494\" articlename=\"M21-1, Part IV, Subpart i, Chapter 1, Section A - Duty to Assist With Providing a Medical Examination or Opinion\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180494/M21-1-Part-IV-Subpart-i-Chapter-1-Section-A-Duty-to-Assist-With-Providing-a-Medical-Examination-or-Opinion\">M21-1, Part IV, Subpart i, 1.A</a>, and </span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><a articleid=\"554400000180498\" articlename=\"M21-1, Part IV, Subpart i, Chapter 2, Section A - Examination Requests Overview\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180498/M21-1-Part-IV-Subpart-i-Chapter-2-Section-A-Examination-Requests-Overview\">M21-1, Part IV, Subpart i, 2.A</a>. </span></span></li></ul></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><div><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"height: 281px; width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">V.iii.5.3.d<a id=\"3d\" name=\"3d\">.</a>  Pre-Hypertension</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"height: 281px; width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><strong><em>Pre-hypertension</em></strong> is generally defined as systolic pressure between 120mm and 139mm and diastolic pressure from 80mm to 89mm.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Pre-hypertension is <strong><em>not</em></strong> a disability for VA purposes.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">If the VA examination (or evidence used in lieu of a VA examination) contains only a diagnosis of pre-hypertension based on readings that do not meet the definition of hypertension or isolated systolic hypertension, do <strong><em>not</em></strong></span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">seek clarification, or</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">grant SC for hypertension based on the diagnosis.   </span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><strong><em>Exception</em></strong>:  Clarification <em>may</em> be required if a current diagnosis of “pre-hypertension” is made where readings exist in the record that meet the regulatory definition of hypertension.  This may indicate</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">conflicting evidence, and/or</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">equivocation by the medical professional on diagnosis or chronicity (particularly if, for example, the facts show a predominance of readings not meeting the regulatory definition of hypertension).  </span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><strong><em>References</em></strong>:  For more information on</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">evaluating medical evidence, see <a articleid=\"554400000014383\" articlename=\"M21-1, Part V, Subpart ii, Chapter 1, Section A - Principles of Reviewing and Weighing Evidence\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000014383/M21-1-Part-V-Subpart-ii-Chapter-1-Section-A-Principles-of-Reviewing-and-Weighing-Evidence\">M21-1, Part V, Subpart ii, 1.A.3</a></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">developing for additional evidence when needed, see <a articleid=\"554400000180487\" articlename=\"M21-1, Part V, Subpart ii, Chapter 3, Section B - Making Partial Rating Decisions\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180487/M21-1-Part-V-Subpart-ii-Chapter-3-Section-B-Making-Partial-Rating-Decisions\">M21-1, Part V, Subpart ii, 3.B.1.a</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">handling examination reports insufficient for rating purposes, see <a articleid=\"554400000180517\" articlename=\"M21-1, Part IV, Subpart i, Chapter 3, Section C - Insufficient Examinations\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180517/M21-1-Part-IV-Subpart-i-Chapter-3-Section-C-Insufficient-Examinations\">M21-1, Part IV, Subpart i, 3.C</a>.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><div><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">V.iii.5.3.e<a id=\"3e\" name=\"3e\">.</a>  Predominant Blood Pressure in Evaluations of Hypertension</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Every level of evaluation specified under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=8c8c1718ddbc2174459adeeef00bc703&amp;node=se38.1.4_1104&amp;rgn=div8\" target=\"_blank\">38 CFR 4.104, DC 7101</a> requires consideration of the <strong><em>predominant</em></strong> (most common or prevailing) blood pressure. Blood pressure may fluctuate depending on a number of variables and disability evaluations must be based on valid evidence demonstrating representative disability.  </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Generally the regulation requires analysis of predominant <em>current</em> readings— readings from the period during which an effective date can be assigned.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">When current predominant blood pressure readings are non-compensable, a 10-percent evaluation may be assigned if</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">continuous medication is required for blood pressure control, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">past diastolic pressure (before medication was prescribed) was predominantly 100 or greater. </span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><strong><em>Important</em></strong>:  Do not assign a 10-percent evaluation based upon a showing of one of the two conjunctive criteria above by invoking the benefit of the doubt rule (<a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=8c8c1718ddbc2174459adeeef00bc703&amp;node=se38.1.3_1102&amp;rgn=div8\" target=\"_blank\">38 CFR 3.102</a> and <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=8c8c1718ddbc2174459adeeef00bc703&amp;node=se38.1.4_13&amp;rgn=div8\" target=\"_blank\">38 CFR 4.3</a> or <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=8c8c1718ddbc2174459adeeef00bc703&amp;node=se38.1.4_17&amp;rgn=div8\" target=\"_blank\">38 CFR 4.7</a><u>)</u>.  When either criterion is simply not shown (for example, the claimant is using prescribed anti-hypertensive medication but diastolic pressure has never been predominantly 100 or greater) the evidence is not in relative equipoise on whether a 10-percent evaluation is appropriate and the disability picture does not more nearly approximate the 10-percent criteria.  </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">However, <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=8c8c1718ddbc2174459adeeef00bc703&amp;node=se38.1.3_1102&amp;rgn=div8\" target=\"_blank\">38 CFR 3.102</a>, <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=8c8c1718ddbc2174459adeeef00bc703&amp;node=se38.1.4_13&amp;rgn=div8\" target=\"_blank\">38 CFR 4.3</a>, and <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=8c8c1718ddbc2174459adeeef00bc703&amp;node=se38.1.4_17&amp;rgn=div8\" target=\"_blank\">38 CFR 4.7</a> may be applicable to whether the evidence supports each criterion, namely</span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">whether diastolic readings before were predominantly 100 or higher or</span></span></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">whether continuous medication is required for control of blood pressure.</span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Use the table below to assist in analyzing predominant blood pressure.</span></span></div><div style=\"margin-left: 9.35pt\"><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"> </span></span></div><div style=\"margin-left: 9.35pt\"><table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" style=\"height: 1339px; width: 467px; border-spacing: 0px; border-collapse: revert;\" summary=\"This is an When-Then table.  Column 1 describes the circumstance, and column 2 provides instructions for analyzing predominant blood pressure.\" width=\"467\"><thead><tr><th scope=\"col\" style=\"width: 50%; padding: 0px;\"><div style=\"text-align: left\"><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><strong>When ...</strong></span></span></div></th><th scope=\"col\" style=\"width: 100%; padding: 0px;\"><div style=\"text-align: left\"><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><strong>Then ...</strong></span></span></div></th></tr></thead><tbody><tr><td style=\"width: 50%; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">determining which diastolic or systolic pressure range is predominant</span></span></div></td><td style=\"width: 50%; padding: 0px;\"><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">make note of the competent and credible evidence of diastolic and systolic readings (see <a articleid=\"554400000014383\" articlename=\"M21-1, Part V, Subpart ii, Chapter 1, Section A - Principles of Reviewing and Weighing Evidence\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000014383/M21-1-Part-V-Subpart-ii-Chapter-1-Section-A-Principles-of-Reviewing-and-Weighing-Evidence\">M21-1, Part V, Subpart ii, 1.A</a>)</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">determine which readings correspond with the various levels of evaluation specified in the diagnostic criteria (for example diastolic readings “100 or more” or “110 or more”), and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">subject to the notes below, conclude that the range with the most qualifying readings is the predominant blood pressure.  </span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><strong><em>Notes</em></strong>: </span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">If there is a relative balance of readings supporting two levels of evaluation for the same time frame, apply <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=8c8c1718ddbc2174459adeeef00bc703&amp;node=se38.1.3_1102&amp;rgn=div8\" target=\"_blank\">38 CFR 3.102</a>, <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=8c8c1718ddbc2174459adeeef00bc703&amp;node=se38.1.4_13&amp;rgn=div8\" target=\"_blank\">38 CFR 4.3</a> and <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=8c8c1718ddbc2174459adeeef00bc703&amp;node=se38.1.4_17&amp;rgn=div8\" target=\"_blank\">38 CFR 4.7</a>. </span></span></li></ul><p style=\"margin-left: 40px\"><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><strong><em>Example</em></strong>:  If there are six diastolic measurements from one doctor in the 100 to 109 range (108, 106, 108, 104, 106, 100) in June, and six diastolic readings from another doctor in the 110 to 119 range (110, 110, 114, 110, 112, 110) the same month, give the benefit of the doubt and assign the higher 20-percent evaluation. </span></span></p><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">If during the evaluation period more than one blood pressure range is supported for at least a month stage the evaluation in accordance with the facts. </span></span></li></ul><p style=\"margin-left: 40px\"><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><strong><em>Example</em></strong>:  Use the readings above but assume second doctor’s readings were taken in November. Assign a 10-percent evaluation based on the June results from the date of claim or date entitlement arose, whichever is the later; stage to 20 percent as of the date of the first readings from November.</span></span></p></td></tr><tr><td style=\"width: 50%; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">considering predominant blood pressure before control with medication</span></span></div></td><td style=\"width: 50%; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">start with the more current of</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">the readings taken as part of the diagnostic workup period leading to the diagnosis of hypertension if medication was prescribed at that time, or</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">the readings taken as part of a subsequent diagnostic workup period leading to the prescription of medication.  </span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><strong><em>Explanation</em></strong>:  These are the readings pertinent to whether hypertensive readings were predominantly in the compensable range before hypertension was brought under control with medication. </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Do not consider </span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">normal blood pressure readings taken long before the diagnosis of hypertensive vascular disease was made, or</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">minimally hypertensive readings prior to active medical surveillance or observation leading to the prescription of medication. </span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><strong><em>Explanation</em></strong>:  These are not pertinent and will impermissibly skew the analysis of the predominant blood pressure.</span></span></div></td></tr><tr><td style=\"width: 50%; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">considering a <em>history</em> of predominant blood pressure for the purposes of a 10 percent evaluation under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=8c8c1718ddbc2174459adeeef00bc703&amp;node=se38.1.4_1104&amp;rgn=div8\" target=\"_blank\">38 CFR 4.104, DC 7101</a></span></span></div></td><td style=\"width: 258%; padding: 0px;\"><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">only consider blood pressure readings obtained when the Veteran was undergoing a diagnostic evaluation for hypertension, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">do not consider other clinical records documenting treatment prior to the diagnostic evaluation for hypertension.</span></span></div></li></ul></td></tr></tbody></table><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"> </span></span></div></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><div><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">V.iii.5.3.f<a id=\"3f\" name=\"3f\">.</a>  Long Term Effects of Hypertension</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Hypertension may</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">exist for years without causing symptoms</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">so increase the cardiac load as to result in hypertrophy of the cardiac muscle or cardiac dilation and decompensation, if sufficiently severe, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">cause arteriosclerosis of uneven distribution that often involves the vessels of one organ to a greater degree than those of the rest of the body, in cases where hypertension is long-standing. </span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">If the hypertension is of sufficient degree to cause significant impairment of circulation to the organ, symptoms will manifest in accordance with the</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">organ involved, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">degree of impairment.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><div><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><div><h3><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">V.iii.5.3.g<a id=\"3g\" name=\"3g\">.</a>  Granting SC for Arteriosclerotic Manifestations Due to Hypertension</span></span></h3></div></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">If additional arteriosclerotic manifestations are subsequently diagnosed in a Veteran with SC hypertension, grant SC on a secondary basis through the relationship to hypertension for any of the following:</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">cerebral arteriosclerosis or thrombosis with hemiplegia</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">nephrosclerosis of the kidneys with impairment of renal function, or</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">myocardial damage or coronary occlusion of the heart. </span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><strong><em>Important</em></strong>:  A claim for benefits is required to adjudicate a secondary SC claim for any of the arteriosclerotic manifestations.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><strong><em>Notes</em></strong>: </span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Address SC for the above-listed cardiovascular conditions through the relationship to the hypertension when a sympathetic reading of the Veteran’s claim reasonably implies a claim for SC for those conditions.</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Arteriosclerosis occurs with advancing age without preexisting hypertension, and may occur in some younger individuals who are predisposed to arterial changes.</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">The existence of arteriosclerosis does not imply/indicate prior hypertension.</span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><strong><em>References</em></strong>:  For more information on </span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">secondary SC, see <a articleid=\"554400000180484\" articlename=\"M21-1, Part V, Subpart ii, Chapter 2, Section D - Secondary Service Connection (SC) and Aggravation of Non-Service-Connected (NSC) Disabilities\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180484/M21-1-Part-V-Subpart-ii-Chapter-2-Section-D-Secondary-Service-Connection-SC-and-Aggravation-of-Non-Service-Connected-NSC-Disabilities\">M21-1, Part V, Subpart ii, 2.D</a>, and</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">sympathetic reading and scope of claim, see <a articleid=\"554400000180486\" articlename=\"M21-1, Part V, Subpart ii, Chapter 3, Section A - Determining the Issues\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180486/M21-1-Part-V-Subpart-ii-Chapter-3-Section-A-Determining-the-Issues\">M21-1, Part V, Subpart ii, 3.A</a>.</span></span></li></ul></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><div><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">V.iii.5.3.h<a id=\"3h\" name=\"3h\">.</a>  Effective Dates of Arteriosclerotic Manifestations Granted Secondary to Hypertension</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">The effective date of any grant of SC for arteriosclerotic manifestations secondary to hypertension is the date of claim or date entitlement arose, whichever is later.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><strong><em>Important</em></strong>:  </span></span></div><ul><li style=\"margin-left: 7.9pt\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Arteriosclerotic manifestations are not considered a worsening of hypertensive vascular disease (hypertension and isolated systolic hypertension) rated under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=8c8c1718ddbc2174459adeeef00bc703&amp;node=se38.1.4_1104&amp;rgn=div8\" target=\"_blank\">38 CFR 4.104, DC 7101</a>.  They are separate conditions which may be secondary to hypertensive vascular disease, but which nonetheless must be evaluated under rating criteria specific to their symptomology and the functions and anatomical localities they affect.  Therefore, <b><i>do not apply </i></b><a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=d44fc4dbe20d19444f7434d251534e7a&amp;node=se38.1.3_1400&amp;rgn=div8\" target=\"_blank\">38 CFR 3.400(o)(2)</a> to allow an effective date prior to the date of claim, as this only applies to increases.</span></span></div></li><li style=\"margin-left: 7.9pt\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">If awarding SC for a disability as within scope of the hypertension claim, apply an effective date based on the date of claim for hypertension.</span></span></div></li></ul><div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><strong><em>References</em></strong>:  For more information on</span></span></div></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">scope of claim, see <a articleid=\"554400000180486\" articlename=\"M21-1, Part V, Subpart ii, Chapter 3, Section A - Determining the Issues\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180486/M21-1-Part-V-Subpart-ii-Chapter-3-Section-A-Determining-the-Issues\">M21-1, Part V, Subpart ii, 3.A</a></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">secondary SC, see <a articleid=\"554400000180484\" articlename=\"M21-1, Part V, Subpart ii, Chapter 2, Section D - Secondary Service Connection (SC) and Aggravation of Non-Service-Connected (NSC) Disabilities\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180484/M21-1-Part-V-Subpart-ii-Chapter-2-Section-D-Secondary-Service-Connection-SC-and-Aggravation-of-Non-Service-Connected-NSC-Disabilities\">M21-1, Part V, Subpart ii, 2.D</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">effective dates, see </span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=d44fc4dbe20d19444f7434d251534e7a&amp;node=se38.1.3_1400&amp;rgn=div8\" target=\"_blank\">38 CFR 3.400</a>, and </span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><a articleid=\"554400000180492\" articlename=\"M21-1, Part V, Subpart ii, Chapter 4, Section A - Effective Dates\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180492/M21-1-Part-V-Subpart-ii-Chapter-4-Section-A-Effective-Dates\">M21-1, Part V, Subpart ii, 4.A</a>.</span></span></div></li></ul></li></ul></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">V.iii.5.3.i<a id=\"3i\" name=\"3i\">.</a>  Separately<br/>Evaluating Hypertension and Heart Disease</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Evaluate hypertension separately from hypertensive heart disease and other types of heart disease. </span></span><div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Evaluate hypertension due to aortic insufficiency, which is usually the isolated systolic type, as part of the condition causing it rather than by a separate evaluation.</span></span></div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><strong><em>Notes</em></strong>: </span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">The cause of hypertension is unknown in the vast majority of cases.</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Do not establish SC for hypertension if the evidence does not contain blood pressure readings as specified in <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=8c8c1718ddbc2174459adeeef00bc703&amp;node=se38.1.4_1104&amp;rgn=div8\" target=\"_blank\">38 CFR 4.104, DC 7101</a>, Note 1. </span></span></div></li></ul></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">V.iii.5.3.j<a id=\"3j\" name=\"3j\">.</a>  Prohibition on Separate Evaluation of Hypertension  and Renal Dysfunction from Nephritis</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=8c8c1718ddbc2174459adeeef00bc703&amp;node=se38.1.4_1115&amp;rgn=div8\" target=\"_blank\">38 CFR 4.115</a> prohibits assignment of separate evaluations for renal dysfunction from <em>nephritis</em> and for <em>hypertension</em> <strong><em>except</em></strong> where</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">the sole renal disability is absence of a kidney (even if that was due to nephritis), or</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">nephritis has progressed to the point where regular dialysis is required.</span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><strong><em>References</em></strong>:  For more information on</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">pyramiding of evaluations for nephritis and hypertension, see <a articleid=\"554400000180593\" articlename=\"M21-1, Part V, Subpart iii, Chapter 7 - Genitourinary Disabilities\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180593/M21-1-Part-V-Subpart-iii-Chapter-7-Genitourinary-Disabilities\">M21-1, Part V, Subpart iii, 7.2.c</a></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">assignment of separate evaluations for nephropathy and hypertension, see <a articleid=\"554400000180593\" articlename=\"M21-1, Part V, Subpart iii, Chapter 7 - Genitourinary Disabilities\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180593/M21-1-Part-V-Subpart-iii-Chapter-7-Genitourinary-Disabilities\">M21-1, Part V, Subpart iii, 7.2.g</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">separating findings that constitute a single disability and the <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=4e9d71906dc581eb11c6e0a86e57ec47&amp;mc=true&amp;node=se38.1.4_114&amp;rgn=div8\" target=\"_blank\">38 CFR 4.14</a> prohibition against pyramiding, see <a articleid=\"554400000180489\" articlename=\"M21-1, Part V, Subpart ii, Chapter 3, Section D - Evaluating Disabilities\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180489/M21-1-Part-V-Subpart-ii-Chapter-3-Section-D-Evaluating-Disabilities\">M21-1, Part V, Subpart ii, 3.D.2.b</a>.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">V.iii.5.3.k<a id=\"3k\" name=\"3k\">.</a>  Evaluating Rheumatic Heart Disease Coexisting With Hypertensive or Arteriosclerotic Heart Disease</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Accepted medical principles do <strong><em>not</em></strong> concede an etiological relationship between rheumatic heart disease and either hypertensive or arteriosclerotic heart disease.  Therefore, do <strong><em>not</em></strong> extend secondary SC to systemic manifestations or arteriosclerosis in areas remote from the heart if the Veteran is SC for rheumatic heart disease.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">If a Veteran who is SC for rheumatic heart disease develops hypertensive or arteriosclerotic heart disease after the applicable presumptive period following military discharge, request a medical opinion to determine which condition is causing the current signs and symptoms.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><strong><em>Note</em></strong>:  If the examiner is unable to separate the effects of one type of heart disease from another, follow the guidance in <a articleid=\"554400000180489\" articlename=\"M21-1, Part V, Subpart ii, Chapter 3, Section D - Evaluating Disabilities\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180489/M21-1-Part-V-Subpart-ii-Chapter-3-Section-D-Evaluating-Disabilities\">M21-1, Part V, Subpart ii, 3.D.2.c</a>.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><div class=\"ng-scope\" style=\"margin-left: 85pt\"></div><div class=\"ng-scope\" style=\"margin-left: 85pt\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div><div class=\"ng-scope\"></div><div class=\"ng-scope\"></div><h2 class=\"ng-scope\"><strong><span style=\"font-size: 16px\"><span style=\"font-family: arial , helvetica , sans-serif\">4<a id=\"4\" name=\"4\">.</a>  Residuals of Cold Injuries</span></span></strong></h2><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><div><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span><br/> </p><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Introduction</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">This topic contains information about residuals of cold injury, including</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#4a\" target=\"_self\">general effects of injury due to cold</a></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#4b\" target=\"_self\">long-term effects of exposure to cold</a></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#4c\" target=\"_self\">granting SC for residuals of cold injuries</a></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#4d\" target=\"_self\">x-ray findings in cold injury cases</a></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">considering </span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#4e\" target=\"_self\">circumstances of service in cold injury cases</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#4f\" target=\"_self\">cold injuries incurred during the Chosin Reservoir Campaign</a>, and</span></span></div></li></ul></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#4g\" target=\"_self\">granting SC for cold injuries incurred during the Chosin Reservoir Campaign</a></span></span><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><div><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Change Date</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">November 15, 2021</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><div><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.5.4.a</span></span><a id=\"4a\" name=\"4a\">.</a>  General Effects of Injury Due to Cold</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Injury due to exposure to extremely cold temperatures causes structural and functional disturbances of</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">small blood vessels</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">cells</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">nerves</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">skin, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">bone.  </span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">The physical effects of exposure may be acute or chronic, with immediate or latent manifestations. </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Examples</em></strong>:  Exposure to</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">damp cold temperatures (around freezing) cause frostnip and immersion or trench foot.</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">dry cold, or temperatures well below freezing, cause frostbite with, in severe cases, loss of body parts, such as fingers, toes, earlobes, or the tip of the nose.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><div><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.5.4.b<a id=\"4b\" name=\"4b\">.</a>  Long-Term Effects of Exposure to Cold</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">The fact that the immediate effects of cold injury may have been characterized as “<em>acute”</em> or “<em>healed”</em> does not preclude development of disability at the original site of injury many years later.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">There does not need to be continuity of symptoms following a cold injury.  Typically symptoms may last for days up to a week or two after the cold injury.  Unless there was a loss (such as part of a hand or foot), the initial injury is followed by a long symptom-free period, after which signs and symptoms may reoccur. </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">An SC cold injury is, therefore, evaluated based on those residuals identified in <a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-B/subject-group-ECFRc88f57fafb24f86/section-4.104\" target=\"_blank\">38 CFR 4.104, DC 7122</a>.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><div><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">V.iii.5.4.c<a id=\"4c\" name=\"4c\">.</a>  Granting SC for Residuals of Cold Injuries</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Grant SC for the residuals of cold injury if</span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">the cold injury was incurred during military service, and</span></span></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">an intercurrent NSC cause cannot be determined.  </span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Notes</em></strong>: </span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">The fact that an NSC systemic disease that could produce similar findings is present, or that other areas of the body not affected by cold injury have similar findings, does not necessarily preclude SC for residual conditions in the cold-injured areas. </span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">When considering the possibility of intercurrent cause, always resolve reasonable doubt in the Veteran’s favor. </span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Reference</em></strong>:  For more information on reasonable doubt, see <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=8c8c1718ddbc2174459adeeef00bc703&amp;node=se38.1.3_1102&amp;rgn=div8\" target=\"_blank\">38 CFR 3.102</a>.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><div><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">V.iii.5.4.d<a id=\"4d\" name=\"4d\">.</a>  X-Ray Findings in Cold Injury Cases </span></span></h3><p></p></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">For appropriate evaluation of cold injuries under the criteria of <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=8c8c1718ddbc2174459adeeef00bc703&amp;node=se38.1.4_1104&amp;rgn=div8\" target=\"_blank\">38 CFR 4.104, DC 7122</a>, it is very important that there be medical evidence addressing whether or not x-ray abnormalities (specifically osteoporosis, subarticular punched out lesions, or osteoarthritis) exist.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">The <em>Cold Injury Residuals</em> </span><span style=\"font-family: arial, helvetica, sans-serif\"><em>Disability Benefits Questionnaire</em></span><span style=\"font-family: arial , helvetica , sans-serif\"> instructs that the x-ray abnormalities (osteoporosis, subarticular punched out lesions, or osteoarthritis) must be confirmed by x-rays.  Once these abnormalities have been documented no further imaging studies are indicated.  This means that x-ray studies do not have to be completed on each and every subsequent examination after the specified abnormalities have been documented. </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">The DBQ asks the examiner whether x-rays have been performed and if so to provide the date of the studies. </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">If an examination is necessary for evaluation purposes, x-ray studies were not performed as part of the examination, and the specified x-ray abnormalities have not been previously documented, return the examination.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>References</em></strong>:  For more information on</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">examination report requirements, see <a articleid=\"554400000180514\" articlename=\"M21-1, Part IV, Subpart i, Chapter 3, Section A - General Criteria for Sufficiency of Examination Reports\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180514/M21-1-Part-IV-Subpart-i-Chapter-3-Section-A-General-Criteria-for-Sufficiency-of-Examination-Reports\">M21-1, Part IV, Subpart i, 3.A</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">handling examinations insufficient for rating purposes, see <a articleid=\"554400000180517\" articlename=\"M21-1, Part IV, Subpart i, Chapter 3, Section C - Insufficient Examinations\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180517/M21-1-Part-IV-Subpart-i-Chapter-3-Section-C-Insufficient-Examinations\">M21-1, Part IV, Subpart i, 3.C</a>. </span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.5.4.e<a id=\"4e\" name=\"4e\">.</a>  Considering Circumstances of Service in Cold Injury Cases</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Consider the circumstances of service as provided in <a href=\"http://www.law.cornell.edu/uscode/text/38/1154\" target=\"_blank\">38 U.S.C. 1154(a)</a> and <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=8c8c1718ddbc2174459adeeef00bc703&amp;node=se38.1.3_1303&amp;rgn=div8\" target=\"_blank\">38 CFR 3.303(a)</a>, even if STRs are not positive for a claimed cold injury.   </span></span><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Also as provided in <a href=\"https://www.law.cornell.edu/uscode/text/38/1154\" target=\"_blank\">38 U.S.C. 1154(b)</a> and <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=8c8c1718ddbc2174459adeeef00bc703&amp;node=se38.1.3_1304&amp;rgn=div8\" target=\"_blank\">38 CFR 3.304(d)</a>, in cases involving cold injuries related to documented combat service, satisfactory lay evidence of service conditions will be accepted if consistent with the circumstances, conditions, or hardships of combat service even if there is no official documentation in service records.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">For example, the Battle of the Bulge (Ardennes/Rhineland) in the winter of 1944/1945 during World War II was known for its extreme cold.  If participation in the Battle of the Bulge is confirmed by the <em>DD </em><em>Form 214, Certificate of Release or Discharge from Active Duty</em>, or personnel records, concede exposure to extreme cold.  If the Veteran engaged in combat with the enemy and the circumstances of service are consistent with claimed service in the Battle of the Bulge, concede exposure to extreme cold.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Afford an examination if the circumstances are consistent with exposure to extreme cold, proving an event in service, and the criteria for a necessary examination are otherwise met. </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Reference</em></strong>:  For more information on determining whether an examination is necessary, see</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=ce2602ebc837f1da23bde2598c47a4f5&amp;mc=true&amp;node=se38.1.3_1159&amp;rgn=div8\" target=\"_blank\">38 CFR 3.159(c)(4)</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a articleid=\"554400000180494\" articlename=\"M21-1, Part IV, Subpart i, Chapter 1, Section A - Duty to Assist With Providing a Medical Examination or Opinion\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180494/M21-1-Part-IV-Subpart-i-Chapter-1-Section-A-Duty-to-Assist-With-Providing-a-Medical-Examination-or-Opinion\">M21-1, Part IV, Subpart i, 1.A</a> and <a articleid=\"554400000180495\" articlename=\"M21-1, Part IV, Subpart i, Chapter 1, Section B - Evidentiary Standards for Finding an Examination or Opinion Necessary\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180495/M21-1-Part-IV-Subpart-i-Chapter-1-Section-B-Evidentiary-Standards-for-Finding-an-Examination-or-Opinion-Necessary\">B</a>.</span></span></div></li></ul></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><div><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.5.4.f<a id=\"4f\" name=\"4f\">.</a>  Considering Cold Injuries Incurred During the Chosin Reservoir Campaign</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">The Chosin Reservoir Campaign was conducted during the Korean War, October 1950 through December 1950, in temperatures of –20ºF or lower.  Many participants in this campaign suffered from frostbite for which they received no treatment and, as a result, there may be no STRs to directly support their claims for frostbite. </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">If the Veteran’s participation in the Chosin Reservoir Campaign is confirmed, concede exposure to extreme cold under the provisions of <a href=\"http://www.law.cornell.edu/uscode/text/38/1154\" target=\"_blank\">38 U.S.C. 1154(a)</a>.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 1.2in\"><div><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.5.4.g<a id=\"4g\" name=\"4g\">.</a>  Granting SC for Cold Injuries Incurred During the Chosin Reservoir Campaign</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Grant SC under the provisions of <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=8c8c1718ddbc2174459adeeef00bc703&amp;node=se38.1.3_1303&amp;rgn=div8\" target=\"_blank\">38 CFR 3.303(a)</a> and <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=8c8c1718ddbc2174459adeeef00bc703&amp;node=se38.1.3_1304&amp;rgn=div8\" target=\"_blank\">38 CFR 3.304(d)</a> if</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">the Veteran has a disability which is diagnosed as a residual of cold injury, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">there are no other circumstances to which this disability may be attributed.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><h2 class=\"ng-scope\"></h2><p class=\"ng-scope\"></p><h2 class=\"ng-scope\"><span style=\"font-size: 16px\"><span style=\"font-family: arial, helvetica, sans-serif\">5<a id=\"5\" name=\"5\">.</a>  Other Cardiovascular Disabilities</span></span></h2><p class=\"ng-scope\"></p><div class=\"ng-scope\"></div><div class=\"ng-scope\"></div><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Introduction</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; vertical-align: top; padding: 0px;\"><div><div class=\"MsoBlockText\"><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">This topic contains information about other cardiovascular disabilities, including</span></span></div><ul><li style=\"margin-left: 7.9pt\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><a href=\"#5a\" target=\"_self\">evaluating Raynaud’s syndrome and Raynaud’s disease</a></span></span></div></li><li style=\"margin-left: 7.9pt\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><a href=\"#5b\" target=\"_self\">testing requirements for peripheral arterial disease</a>, and</span></span></div></li><li style=\"margin-left: 7.9pt\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><a href=\"#5c\" target=\"_self\">changes in the rating schedule for the cardiovascular system</a>. </span></span></div></li></ul></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Change Date</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">February 5, 2024</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">V.iii.5.5.a<a id=\"5a\" name=\"5a\">.</a>  Evaluating Raynaud’s Syndrome and Raynaud’s Disease</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Raynaud’s syndrome and Raynaud’s disease are unrelated in etiology and severity.  Raynaud’s disease is more common and tends to be less severe than Raynaud’s syndrome. </span></span></div><ul><li style=\"margin-left: 7.9pt\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Raynaud’s syndrome (also known as secondary Raynaud’s phenomenon) is typically caused by autoimmune diseases such as scleroderma, lupus, rheumatoid arthritis, atherosclerosis, or polycythemia.  This condition is rated under <a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-B/subject-group-ECFRc88f57fafb24f86/section-4.104\" target=\"_blank\">38 CFR 4.104, DC 7117</a>.</span></span></div></li><li style=\"margin-left: 7.9pt\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Raynaud’s disease (also known as primary Raynaud’s phenomenon) is idiopathic (due to an unknown cause).  This condition is rated under <a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-B/subject-group-ECFRc88f57fafb24f86/section-4.104\" target=\"_blank\">38 CFR 4.104, DC 7124</a>.</span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><b><i>Note</i></b>:  A Veteran cannot receive simultaneous ratings under both <a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-B/subject-group-ECFRc88f57fafb24f86/section-4.104\" target=\"_blank\">38 CFR 4.104, DC 7117 and DC 7124</a> because Raynaud’s disease and Raynaud’s syndrome cannot be comorbid conditions. </span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">V.iii.5.5.b<a id=\"5b\" name=\"5b\">.</a>  Testing Requirements for Peripheral Arterial Disease</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Under <a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-B/subject-group-ECFRc88f57fafb24f86/section-4.104\" target=\"_blank\">38 CFR 4.104, DC 7114, Note 2</a>, peripheral arterial disease may be evaluated utilizing ankle brachial index, ankle pressure, toe pressure, or transcutaneous oxygen tension values. </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">The ankle/brachial index is the most common type of testing for evaluating peripheral arterial disease.  In some situations, ankle/brachial index measurement is not appropriate for a given disability.  In those cases, ankle pressure, toe pressure, or transcutaneous oxygen tension values are more appropriate tests.</span></span></div><ul><li style=\"margin-left: 7.9pt\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">If the ankle pressure, toe pressure, and/or transcutaneous oxygen tension measurements are not of record, evaluate based on the ankle/brachial index unless the examiner indicates that one of the other tests is necessary.</span></span></div></li><li style=\"margin-left: 7.9pt\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><span lang=\"EN\">If more than one test result is available, evaluate using the test result that results in the highest evaluation.  </span></span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">V.iii.5.5.c<a id=\"5c\" name=\"5c\">.</a>  Changes in the Rating Schedule for the Cardiovascular System</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">The rating criteria for cardiovascular conditions have undergone historical changes.  Recent full-scale historical revisions were effective on the following dates:</span></span></div><ul><li style=\"margin-left: 7.9pt\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">November 14, 2021, and</span></span></div></li><li style=\"margin-left: 7.9pt\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">January 12, 1998.</span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><b><i>Notes</i></b>: </span></span></div><ul><li style=\"margin-left: 7.9pt\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">These changes in the rating criteria</span></span></div><ul><li style=\"margin-left: 7.9pt\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">are not considered liberalizing, and</span></span></div></li><li style=\"margin-left: 7.9pt\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">should not be the basis for a reduction in disability rating unless medical evidence establishes that the disability has actually improved. </span></span></div></li></ul></li><li style=\"margin-left: 7.9pt\"><div style=\"margin-left: 7.9pt\"><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">A regulatory change to <a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-B/subject-group-ECFRc88f57fafb24f86/section-4.104\" target=\"_blank\">38 CFR 4.104, DC 7122</a> effective August 13, 1998, further revised, but did not substantively change, the evaluation criteria of long-term effects of cold injury residuals.</span></span></div></li></ul><div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><em><strong>References</strong></em>:  For more information on </span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">revised rating schedule criteria and effective dates, see <a articleid=\"554400000180492\" articlename=\"M21-1, Part V, Subpart ii, Chapter 4, Section A - Effective Dates\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180492/M21-1-Part-V-Subpart-ii-Chapter-4-Section-A-Effective-Dates\">M21-1, Part V, Subpart ii, 4.A.6</a>, and</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">evaluating disabilities following rating schedule readjustment, see <a articleid=\"554400000180489\" articlename=\"M21-1, Part V, Subpart ii, Chapter 3, Section D - Evaluating Disabilities\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180489/M21-1-Part-V-Subpart-ii-Chapter-3-Section-D-Evaluating-Disabilities\">M21-1, Part V, Subpart ii, 3.D.2</a>.  </span></span></li></ul></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><p class=\"ng-scope\" style=\"text-align: right\"><span style=\"font-family: arial, helvetica, sans-serif\"><span style=\"font-size: 11px\">﻿﻿<a articleid=\"554400000180881\" articlename=\"M21-1, Part V, Subpart iii, Chapter 4, Section B - Tuberculosis\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180881/M21-1-Part-V-Subpart-iii-Chapter-4-Section-B-Tuberculosis\">&lt;-- Previous Section</a>  <a articleid=\"554400000014523\" articlename=\"M21-1, Part V, Subpart iii, Chapter 6 - Digestive Disabilities\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000014523/M21-1-Part-V-Subpart-iii-Chapter-6-Digestive-Disabilities\">Next Section --&gt;</a></span></span></p><p class=\"ng-scope\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"#top\" target=\"_self\"><span style=\"font-size: 11px\">To Top</span></a></span></p><p class=\"ng-scope\"></p></div>\n</div>",
  "external_links": [
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=055c1bf4970910e4b257cfd824ce0b59&node=se38.1.3_1114&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=35b52ec77cd5f89200838792a366496d&node=se38.1.4_1104&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=4e9d71906dc581eb11c6e0a86e57ec47&mc=true&node=se38.1.4_114&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=730552af9f371c1ffbf4acea2daa806b&node=se38.1.3_1816&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=8c8c1718ddbc2174459adeeef00bc703&node=se38.1.3_1102&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=8c8c1718ddbc2174459adeeef00bc703&node=se38.1.3_1303&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=8c8c1718ddbc2174459adeeef00bc703&node=se38.1.3_1304&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=8c8c1718ddbc2174459adeeef00bc703&node=se38.1.3_1306&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=8c8c1718ddbc2174459adeeef00bc703&node=se38.1.3_1307&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=8c8c1718ddbc2174459adeeef00bc703&node=se38.1.3_1309&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=8c8c1718ddbc2174459adeeef00bc703&node=se38.1.3_1310&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=8c8c1718ddbc2174459adeeef00bc703&node=se38.1.3_16&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=8c8c1718ddbc2174459adeeef00bc703&node=se38.1.4_1104&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=8c8c1718ddbc2174459adeeef00bc703&node=se38.1.4_1115&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=8c8c1718ddbc2174459adeeef00bc703&node=se38.1.4_13&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=ce2602ebc837f1da23bde2598c47a4f5&mc=true&node=se38.1.3_1159&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=ce8e46cb71688f26d85a16832bd8cdf0&mc=true&node=se38.1.4_1104&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=d44fc4dbe20d19444f7434d251534e7a&node=se38.1.3_1400&rgn=div8",
    "http://www.law.cornell.edu/uscode/text/38/1154",
    "https://www.ecfr.gov/cgi-bin/text-idx?SID=8c8c1718ddbc2174459adeeef00bc703&node=se38.1.4_17&rgn=div8",
    "https://www.ecfr.gov/cgi-bin/text-idx?SID=aa6453d39e01ace124f6a68c2af719c9&mc=true&node=se38.1.4_1115&rgn=div8",
    "https://www.ecfr.gov/cgi-bin/text-idx?SID=d05d5d2e780aa4261e1a7e8fe538e0ab&mc=true&node=se38.1.4_114&rgn=div8",
    "https://www.ecfr.gov/current/title-38/chapter-I/part-3/subpart-A/subject-group-ECFR39056aee4e9ff13/section-3.309",
    "https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-A/section-4.14",
    "https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-B/subject-group-ECFRc88f57fafb24f86/section-4.100",
    "https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-B/subject-group-ECFRc88f57fafb24f86/section-4.104",
    "https://www.law.cornell.edu/uscode/text/38/1154"
  ],
  "scraped_at": "2025-06-16T22:44:48.867451",
  "next_section": "https://www.knowva.ebenefits.va.gov/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000014523/M21-1-Part-V-Subpart-iii-Chapter-6-Digestive-Disabilities"
}